Document:

Exhibit 4.4

 

 

 

BELLUS HEALTH INC.

 

NOTICE AND 

MANAGEMENT INFORMATION CIRCULAR

FOR THE

ANNUAL AND SPECIAL MEETING

OF COMMON SHAREHOLDERS

TO BE HELD ON MAY 8, 2019

 

March 13, 2019

 

     

     

    

 

BELLUS HEALTH INC.

 

NOTICE OF ANNUAL AND SPECIAL MEETING
OF SHAREHOLDERS

 

NOTICE is
hereby given that the annual and special meeting (the “Meeting”) of the common shareholders of BELLUS Health
Inc. (the “Company”) will be held at the offices of the Company, at 275 Armand Frappier Blvd., Laval, on
May 8, 2019 at 11:00 AM, Montréal time, for the following purposes:

 

		(i)	to receive and consider the annual report of the directors
to the shareholders and the financial statements of the Company for the financial year ended December 31, 2018, and the report
of the auditors thereon;

 

		(ii)	to elect each of the directors for the ensuing year;

 

		(iii)	to appoint KPMG LLP, Chartered Accountants, as auditors of the Company and to authorize the Audit
Committee to fix the auditors’ remuneration;

 

		(iv)	to adopt a special resolution, the text of which is set out in Schedule “A”
to the management information circular of the Company dated March 13, 2019 (the “Circular”) authorizing
the Board of Directors of the Company to amend the articles of the Company to effect a consolidation of all of the issued and outstanding
common shares of the Company (the “Common Shares”), such that the trading price of the post-consolidation Common
Shares is between US$5.00 and US$7.50 per post-consolidation Common Share;

 

and

 

		(v)	to transact such further and other business as may properly be brought before the Meeting or any
adjournment thereof.

 

DATED at Montréal, Québec,
Canada, March 13, 2019.

 

	 	BY ORDER OF THE BOARD OF DIRECTORS
	 	 
	 	(signed) Sébastien Roy
	 	Corporate Secretary

 

SHAREHOLDERS MAY EXERCISE THEIR VOTING
RIGHTS BY ATTENDING THE MEETING OR BY COMPLETING A FORM OF PROXY. SHAREHOLDERS WHO ARE UNABLE TO BE PRESENT IN PERSON AT THE MEETING
ARE REQUESTED TO COMPLETE, DATE AND SIGN THE ENCLOSED FORM OF PROXY AND MAIL IT TO THE COMPANY, C/O COMPUTERSHARE INVESTOR
SERVICES INC., IN THE ENVELOPE PROVIDED FOR THAT PURPOSE. PLEASE REFER TO THE ACCOMPANYING MANAGEMENT INFORMATION CIRCULAR
FOR ADDITIONAL PARTICULARS.

 

     

     

    

 

Table of Contents 

 

	PART 1. VOTING INFORMATION	4
	 	 
	Solicitation of Proxies	4
	Appointment and Revocation of Proxies	4
	Registered Common Shareholders	4
	Non-Registered Common Shareholders	5
	Voting of Proxies	5
	Voting Shares and Principal Holders thereof	6
	 	 
	PART 2. Business of the Meeting	6
	 	 
	Presentation of Financial Statements and Auditor’s Report	6
	Election of Directors	6
	Auditors of the Company	9
	Share Consolidation 	9
	 	 
	PART 3. statement of Executive Compensation	11
	 	 
	Compensation of Directors and Executives	11
	Equity Compensation Plans	20
	Securities Authorized for Issuance under Equity Compensation Plans	24
	Indebtedness of Directors and Executive Officers	24
	 	 
	PART 4. REPORT ON CORPORATE GOVERNANCE AND OTHER ITEMS	24
	 	 
	Interest of Informed Persons In Material Transactions and Management Contracts	26
	2019 Shareholder Proposals	26
	Additional Information	26
	Approval by Directors	26
	 	 
	Schedule “A” – SHARE CONSOLIDATION RESOLUTION	A-1
	 	 
	Schedule “B” – CORPORATE GOVERNANCE PRACTICES	B-1
	 	 
	Schedule “C” – BOARD OF DIRECTORS MANDATE	C-1

 

    	 	3	 

     

    

 

MANAGEMENT INFORMATION CIRCULAR

 

PART
1.

VOTING
INFORMATION

 

This management information
circular (the “Circular”) is furnished in connection with the solicitation by the management of BELLUS Health Inc.
(the “Company”) of proxies to be voted at the annual and special meeting of common shareholders (the “Meeting”),
to be held at the offices of the Company, at 275 Armand Frappier Blvd., Laval, on May 8, 2019 at 11:00 AM, Montréal
time, for the purposes set forth in the accompanying notice of the Meeting, and at any adjournment thereof. Except as otherwise
stated, the information contained herein is given as at March 13, 2019, all dollar amounts and references to $ or to CDN$ are to
Canadian dollars.

 

Solicitation of Proxies

 

The enclosed proxy
is being solicited by the management of the Company and the expenses of solicitation of proxies will be borne by the Company.
The solicitation will be made primarily by mail; however, officers and regular employees of the Company may also solicit proxies
by telephone, telecopier, electronic mail or in person.

 

Appointment and Revocation of Proxies

 

The persons named
in the enclosed form of proxy are directors or officers of the Company. Each shareholder is entitled to appoint any other person
to represent him at the Meeting, and at any adjournment thereof.

 

A shareholder desiring
to appoint another person (who need not be a shareholder) to represent him at the Meeting, and at any adjournment thereof, may
do so either by striking out the names of the management nominees set forth in the form of proxy and by inserting such person’s
name therein or by completing another proper form of proxy and, in either case, sending the completed proxy in the enclosed reply
envelope for delivery before the Meeting, or any adjournment thereof, or by depositing such proxy with the Chairman on the day
of the Meeting, at the Meeting or any adjournment thereof.

 

A shareholder giving
a proxy pursuant to this solicitation may revoke any such proxy by instrument in writing executed by the shareholder or by his
attorney duly authorized in writing, or if the shareholder is a corporation, executed under its corporate seal or by an officer
or attorney duly authorized in writing, and deposited with the Company, c/o Computershare Investor Services Inc., Attention: Proxy
Department, 100 University Avenue, 9th Floor, North Tower, Toronto, Ontario M5J 2Y1, at any time up to and including the close
of business two business days preceding the day of the Meeting, or any adjournment thereof, or with the Chairman on the day of
the Meeting, at the Meeting or any adjournment thereof, before any vote is cast under the proxy’s authority.

 

Registered Common Shareholders

 

Holders of common
shares of the capital of the Company (the “Common Shares”) listed as shareholders at the close of business on
March 29, 2019, will be entitled to vote at the Meeting, or any adjournment thereof, either in person or by proxy, in respect of
all matters which may properly come before the Meeting, or any adjournment thereof, except to the extent that such shareholder
has subsequently (after the Record Date) transferred any such Common Shares, and the transferee of those Common Shares establishes
such transferee shareholder’s ownership of such Common Shares and requests, no later than two Business Days prior to the
Meeting and requests in writing with sufficient evidence of such transfer of ownership, that such transferee shareholder’s
name be included in the list of shareholders prepared by the Transfer Agent for the Meeting. In such case, only the new transferee
shareholder will be entitled to vote such Common Shares on each matter to be acted upon at the Meeting.

 

    	 	4	 

     

    

 

Non-Registered Common Shareholders

 

The names of the
shareholders whose shares are held in the name of a broker or another intermediary will not appear on the list of shareholders
of the Company. If you are not a registered shareholder of the Company, in order to vote you must a) obtain the material relating
to the Meeting from your broker or other intermediary; b) complete the request for voting instructions sent to you by the
broker or other intermediary; and c) follow the directions of the broker or other intermediary with respect to voting procedures.

 

In accordance with
National Instrument 54-101 adopted by the Canadian Securities Administrators entitled “Communication with Beneficial Owners
of Securities of a Reporting Issuer”, the Company is distributing copies of the material related to the Meeting to clearing
agencies and intermediaries for distribution to non-registered holders. Such agencies and intermediaries must forward the material
related to the Meeting to non-registered holders and often use a service company (such as Broadridge Financial Solutions in Canada)
to permit you, if you are not a registered shareholder, to direct the voting of the Common Shares which you beneficially own. If
you are a non-registered shareholder of the Company, you may revoke voting instructions which have been given to an intermediary
at any time by written notice to the intermediary. If you are a non-registered shareholder of the Company, you should submit your
voting instructions to your intermediary or broker in sufficient time to ensure that your votes are received, from your intermediary
or broker, by Computershare Investor Services Inc. on behalf of the Company, as set forth under the heading “Appointment
and Revocation of Proxies”.

 

Voting of Proxies

 

The persons named
in the enclosed form of proxy will vote or withhold from voting the shares in respect of which they are appointed in accordance
with the directions of the shareholders appointing them.

 

In the absence
of shareholder directions, Common Shares will be voted:

 

		a.	FOR the election as directors of each of those persons
hereinafter named as management’s nominees;

 

		b.	FOR the appointment of KPMG LLP, Chartered Accountants, as auditors of the Company and the authorization
of the Audit Committee to fix the auditors’ remuneration; and

 

		c.	FOR the special resolution authorizing the Board of Directors of the Company to amend its articles
to effect a consolidation of all of the outstanding Common Shares. 

 

All matters to be
voted upon at the Meeting will be decided by a majority of the votes cast by the shareholders entitled to vote thereon; except
as regards the special resolution mentioned above which will require approval by 66 2⁄3% of the votes cast by the shareholders
entitled to vote thereon.

 

The enclosed form
of proxy confers discretionary authority upon the persons named therein with respect to amendments or variations to matters identified
in the accompanying notice of the Meeting or with respect to such other matters as may properly come before the Meeting, or any
adjournment thereof. At the date hereof, the management of the Company knows of no such amendments, variations or other matters
to be presented for action at the Meeting, or any adjournment thereof. However, if any other matters which are not now known to
management should properly come before the Meeting, or any adjournment thereof, the persons named in the enclosed form of proxy
will vote on such matters in accordance with their best judgment.

 

    	 	5	 

     

    

 

Voting Shares and Principal Holders
thereof

 

As at March 13, 2019,
there were 157,956,173 Common Shares outstanding, each of which entitles its holder to one vote at the Meeting. To the knowledge
of the directors and officers of the Company, based on publicly available information, as at March 13, 2019, no person beneficially
owned, directly or indirectly, or exercised control or direction over, shares of the Company carrying 10% or more of the voting
rights attached to all outstanding voting shares of the Company, except as follows:

 

	Name	Number of Common Shares	Percentage of class
	OrbiMed Advisors LLC (“OrbiMed”)	21,310,300	13.5%
	Victoria Square Ventures Inc. (“VSVI”)	17,775,831	11.3%
	Rocabe Investments Inc. (“Rocabe”)	16,433,318	10.4%

 

PART
2.

Business
of the Meeting

 

Presentation of Financial Statements
and Auditor’s Report

 

The audited consolidated
financial statements of the Company, the report of the auditors thereon, and the management’s discussion and analysis thereof
for the financial year ended December 31, 2018, are contained in the 2018 annual report of the Company and will be tabled
at the Meeting, but the approval of the shareholders in respect thereto is not required.

 

Election of Directors

 

Eight directors are
to be elected at the Meeting. The Board of Directors of the Company (the “Board”) recommends that shareholders
vote for the election of each of the nominees whose names are set forth below. The persons named in the enclosed form of proxy
intend to cast the votes to which the shares represented by such proxy are entitled FOR the election of each of the nominees whose
names are set forth below unless otherwise directed by the shareholders appointing them.

 

The Board has a majority
voting policy. This means that if a director receives more “withhold” votes than “for” votes at the annual
meeting of shareholders, then the director will immediately tender his or her resignation to the Chairman. This would be effective
if accepted by the Board. The Human Resources and Governance Committee will consider a director’s offer to resign and make
a recommendation to the Board as to whether to accept it. Absent exceptional circumstances, the resignation will be accepted and
will be effective when accepted by the Board. The director who tenders a resignation pursuant to this policy will not participate
in any meeting of the Board or of the Human Resources and Governance Committee at which the resignation is considered. The Board
will have 90 days from the annual meeting to make and disclose by news release its decision, a copy of which will be provided to
the Toronto Stock Exchange (“TSX”). If the Board determines not to accept a resignation, the news release will
fully state the reasons for that decision. This policy does not apply in circumstances involving contested director elections.

 

Management does not
contemplate that any of the nominees will be unable to serve as a director, but, if that should occur for any reason at or prior
to the Meeting, the persons named in the enclosed form of proxy reserve the right to vote for another nominee at their discretion,
unless instructions have been received from a particular shareholder to withhold its shares from voting with respect to the election
of directors. Each director elected will hold office until the next annual meeting of shareholders or until his successor is duly
elected, unless his office is earlier vacated in accordance with the by-laws of the Company. All of the people named in the table
below are now members of the Board and have been during the period indicated.

 

    	 	6	 

     

    

 

The following table
states the names of all the persons proposed by management to be nominated for election as directors, their municipality, province
or state and country of residence, their age, their principal occupation during the past five years, their position and office
held with the Company, the period during which each proposed nominee has served as a director and the number of Common Shares beneficially
owned, directly or indirectly, by each of them or over which they exercise control or direction.

 

	
        Name and Municipality

        of Residence
	
        Age

        (as at

        March 13,

        2019)
	Principal Occupation During Past Five

Years	Office	Period during which

served as a Director	Number of Common

Shares Beneficially

 Owned, Controlled or

Directed (1)
	
        Dr. Francesco Bellini, O.C. (2) 

        Calgary, Alberta, Canada
	71	Chairman of the Board of Picchio International Inc. (a management and holding company)	Chairman of the Board	2002-2019	3,059,947 (3)
	
        Roberto Bellini (2)

        Montreal, Québec, Canada
	39	President and Chief Executive Officer of the Company	Director	2009-2019	18,548,540 (4)
	
        Dr. Youssef L. Bennani (5)

        Lorraine, Québec, Canada
	58	Chairman of the Board of Domain Therapeutics (6)	Director	2017-2019	394,737
	
        Franklin M. Berger, CFA (7) 

        New York, New York, United States
	69	Consultant	Director	2010-2019	1,452,108
	
        Dr. Clarissa Desjardins

        Montreal, Québec, Canada
	52	Chief Executive Officer of Clementia Pharmaceuticals Inc.	Director	2017-2019	52,632
	
        Chau Q. Khuong (8)

        New York, New York, United States
	43	
        Private Equity Partner of OrbiMed

        Advisors LLC
	Director	2018-2019	NIL
	
        Pierre Larochelle (2), (5), (7)

        Montréal, Québec, Canada
	47	
        Vice President, Investments

        of Power Corporation of Canada (a diversified
        management and holding company)
	Director	2009-2019	275,650
	
        Joseph Rus (5), (7)

        Toronto, Ontario, Canada
	73	Consultant	Director	2009-2019	NIL

 

		(1)	The information as to the Common Shares beneficially owned,
controlled or directed, not being within the knowledge of the Company, has been furnished by the respective candidates individually
as at March 13, 2019.

		(2)	Pursuant to Board representation agreements dated April
16, 2009 between the Company and each of VSVI and a predecessor to Rocabe (the “2009 Board Representation Agreements”),
each of VSVI and Rocabe is entitled to cause two nominees to be included in the list of management nominees to be proposed for
election to the Board at each shareholders meeting occurring following that date. VSVI’s and Rocabe’s right to two
nominees each shall terminate on the date each of VSVI, on the one hand, and Rocabe, FMRC Family Trust (“FMRC”),
a trust of which Dr. Francesco Bellini, Chairman of the Board of the Company, and Mr. Roberto Bellini, President and Chief Executive
Officer of the Company, are beneficiaries and 1324286 Alberta Limited (“AlbertaCo”), a wholly-owned subsidiary
of the FMRC, collectively, on the other hand, ceases to beneficially hold at least 7.5% of the issued and outstanding Common Shares.
Despite their rights, VSVI has only nominated one candidate, being Mr. Larochelle, and Rocabe has only nominated one candidate,
being Dr. Bellini.

		(3)	Dr. Bellini is the registered holder of 693,889 Common
Shares. FMRC and AlbertaCo own 2,366,058 Common Shares, which shares are shown in Dr. Bellini’s share ownership.

		(4)	Mr. Bellini is the registered holder of 2,115,222 Common
Shares and has a beneficial interest in 16,433,318 Common Shares through his 50% interest in Rocabe.

		(5)	Member of the Human Resources and Governance Committee.

		(6)	From 2013 to 2017, Dr. Bennani was Site Head and Vice-President
of R&D at Vertex Pharmaceuticals Canada Inc., a research and development company.

		(7)	Member of the Audit Committee.

		(8)	Pursuant to a Board representation agreement dated December
18, 2018 between the Company and OrbiMed (the “2018 Board Representation Agreement”), OrbiMed is entitled to
cause one nominee to be included in the list of management nominees to be proposed for election to the Board at each shareholders
meeting occurring following that date. OrbiMed’s right to one nominee shall terminate on the date OrbiMed ceases to beneficially
hold at least 10% of the issued and outstanding Common Shares. OrbiMed’s nominated candidate
is Mr. Khuong.

 

Corporate Cease Trade Orders or Bankruptcies

 

To the knowledge
of the directors and officers of the Company, other than as set forth below, no proposed director of the Company:

 

(a)       is,
as at the date of the Circular, or has been, within 10 years before the date of the Circular, a director, chief executive officer
or chief financial officer of any company, that,

 

    	 	7	 

     

    

 

		(i)	was subject to a cease trade order, an order similar to
a cease trade order or an order that denied the relevant company access to any exemption under securities legislation that was
issued while the proposed director was acting in the capacity as director, chief executive officer or chief financial officer
that was in effect for a period of more than 30 consecutive days; or

 

		(ii)	was subject to a cease trade order, an order similar to a cease trade order or an order that denied
the relevant company access to any exemption under securities legislation that was issued after the proposed director ceased to
be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while that person
was acting in the capacity as director, chief executive officer or chief financial officer that was in effect for a period of more
than 30 consecutive days; or

 

(b)       is,
as at the date of the Circular, or has been within 10 years before the date of the Circular, a director or executive officer of
any company, that, while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity,
became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any
proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets;
or

 

(c)       has,
within the 10 years before the date of the Circular, become bankrupt, made a proposal under any legislation relating to bankruptcy
or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver,
receiver manager or trustee appointed to hold its assets.

 

Mr. Pierre Larochelle
resigned as President and CEO and as a director of Adaltis on July 13, 2009. In August 2009, Adaltis filed a voluntary assignment
in bankruptcy under the Bankruptcy and Insolvency Act (Canada) (the “BIA”).

 

Directors’ Attendance at Board and
Committee Meetings

 

The following table
set forth the number of meetings held by the Board and each of its Committees during the fiscal year ended December 31, 2018, and
the attendance of each director at those meetings, or, in the case of Committees of the Board, the attendance of each member of
such Committees.

 

Board and Board Committee Attendance
Record from January 1 to December 31, 2018 

 

	Director	Board	Audit	Human Resources

and Governance	Independent

Directors 
	Dr. Francesco Bellini	7/7	-	-	-
	Roberto Bellini	7/7	-	-	-
	Dr. Youssef L. Bennani 	7/7	-	2/2	1/1
	Franklin M. Berger	7/7	4/4	-	1/1
	Dr. Clarissa Desjardins 	6/7	-	-	1/1
	Chau Q. Khuong (1)	N/A	-	-	N/A
	Pierre Larochelle 	7/7	4/4	2/2	1/1
	Joseph Rus	6/7	4/4	2/2	1/1

 

		(1)	Mr. Khuong was elected
to the Board effective December 18, 2018. He did not attend meetings prior to that date.

 

    	 	8	 

     

    

 

Other Board Memberships 

 

The following table
identifies, in respect of the fiscal year ended December 31, 2018, the current directors of the Company who also act as directors
for other reporting issuers.

 

	Name	Name of issuer	Name of Exchange or Market
	Franklin M. Berger	
        Five Prime Therapeutics Inc.

         

        Immune Design Corp.

        ESSA Pharma Inc.

        Proteostasis Therapeutics Inc.

        Tocagen Inc.

        Kezar Life Sciences Inc.
	
        National Association of Securities Dealers
        Automated Quotations (“NASDAQ”)

        NASDAQ

        TSX Venture Exchange (“TSXV”)
        and NASDAQ

        NASDAQ

        NASDAQ

        NASDAQ

	Chau Q. Khuong	
        Aerpio Pharmaceuticals Inc.

        Synlogic Inc.
	
        NASDAQ

        NASDAQ

	Dr. Clarissa Desjardins	Clementia Pharmaceuticals Inc.	NASDAQ

 

Directors’ and Officers’ Insurance

 

The Company provides
insurance for the benefit of its directors and officers against liability incurred by them in these capacities. The current aggregate
policy limit is $20,000,000, the first $100,000 of certain claims being deductible and payable by the Company. The premium is $42,467
for a twelve-month term ending October 16,
2019. This premium, which has not been specifically allocated between directors as a group and officers as a group, was paid entirely
by the Company.

 

Auditors of the Company

 

KPMG LLP, Chartered
Accountants, have been the auditors of the Company since September 1995. The Board recommends that shareholders vote for the appointment
of KPMG LLP, Chartered Accountants, as auditors of the Company and the authorization of the Audit Committee to fix the auditors’
remuneration. The persons named in the enclosed form of proxy intend to cast the votes to which the shares represented by such
proxy are entitled FOR the reappointment of KPMG LLP, Chartered Accountants, as auditors of the Company for the term expiring with
the next annual meeting of shareholders, and to authorize the Audit Committee to fix their remuneration, unless otherwise directed
by the shareholders appointing them.

 

Share Consolidation

 

At the Meeting, shareholders
will be asked to consider a special resolution (the “Share Consolidation Resolution”) authorizing the Board
to amend the articles of the Company to effect a consolidation of all of the issued and outstanding Common Shares (the “Share
Consolidation”), such that the trading price of the post-consolidation Common Shares is between US$5.00 and US$7.50 per
post-consolidation Common Share, as may be determined by the Board in its sole discretion (the “Consolidation Ratio”).

 

The Board believes
that is in the best interests of the Company to have the authority to implement the Share Consolidation. The potential benefits
of a higher post-consolidation share price include the ability to meet the initial listing requirements of major exchanges in the
United States in the event that the Company determines to pursue such a listing.

 

To be effective,
the Canada Business Corporations Act (the “CBCA”) requires that the Share Consolidation Resolution be
approved by a special resolution of the shareholders, being a majority of not less than two-thirds (2/3) of the votes cast by shareholders
present in person or by proxy at the Meeting. In addition to the approval of the shareholders, the Share Consolidation requires
the approval of the TSX.

 

    	 	9	 

     

    

 

Although shareholders’
approval for the Share Consolidation is being sought at the Meeting, the Share Consolidation would become effective at a date in
the future to be determined by the Board if and when it is considered to be in the best interest of the Company to implement the
Share Consolidation. The Board may, in its sole discretion, determine not to implement the Share Consolidation at any time after
the Meeting without further action on the part of or notice to the shareholders.

 

The full text of
the Share Consolidation Resolution approving the proposed Share Consolidation is attached to this Circular as Schedule “A”.

 

The Board believes
that the proposed Share Consolidation is in the best interest of the Company and its shareholders and unanimously recommends that
shareholders vote FOR the Share Consolidation Resolution.

 

Unless authority
to vote is withheld, the persons named in the accompanying form of proxy intend to vote FOR the Share Consolidation Resolution.

 

Principal Effects
of the Share Consolidation

 

If approved and implemented,
the Share Consolidation will occur simultaneously for all the Common Shares and the Consolidation Ratio will be the same for all
the Common Shares. Except for any variances attributable to fractional shares, the change in the number of issued and outstanding
Common Shares that will result from the Share Consolidation will cause no change in the capital attributable to the Common Shares
and will not materially affect any Shareholder’s percentage ownership in the Corporation, even though such ownership will
be represented by smaller number of Common Shares.

 

In addition, the
Share Consolidation will not materially affect any shareholder’s proportionate voting rights. Each Common Share outstanding
after the Share Consolidation will be entitled to one vote and will be fully paid and non-assessable.

 

No fractional Common
Shares will be issued in connection with the Share Consolidation and, in the event that a shareholder would otherwise be entitled
to receive a fractional share upon such Share Consolidation, the number of Common Shares to be received by such shareholder will
be rounded up or down to the nearest whole Common Share.

 

If the proposed Share
Consolidation is approved by the shareholders and all regulatory requirements are complied with, including the approval of the
TSX, and implemented by the Board, following the announcement by the Company of the effective date of the Share Consolidation,
registered shareholders will be sent a letter of transmittal by the Company’s transfer agent, Computershare Investor Services
Inc., containing instructions on how to exchange their share certificates representing pre-consolidation Common Shares for new
share certificates representing post-consolidation Common Shares. Non-registered shareholders holding their Common Shares through
a bank, broker or other nominee should note that such banks, brokers or other nominees may have different procedures for processing
the Share Consolidation than those that will be put in place by the Company for the registered shareholders. If you hold your Common
Shares with such a bank, broker or other nominee and if you have any question in this regard, you are encouraged to contact your
nominee.

 

    	 	10	 

     

    

 

PART
3.

statement
of Executive Compensation

 

Compensation of Directors and Executives

 

Compensation Discussion and Analysis

 

Objectives
of the Compensation Program

 

The Company’s
current remuneration program plays an important role in attracting and retaining key members of the senior executive team. The
Company is committed to a compensation policy that is competitive and drives business performance.

 

What
the Compensation Program is designed to reward

 

The Compensation
Program is designed to reward the senior executive team for implementing key strategies, both in the short- and the long-term,
that will allow the Company to advance its development of products that provide innovative health solutions and address critical
unmet medical needs, to enhance its share value, and, thereby, create economic value. Actual rewards are directly linked to the
results of the Company.

 

Remuneration and
incentive components have been established to compete with remuneration practices of similar companies that are involved in the
biopharmaceutical and pharmaceutical industries. To establish base salary and bonus compensation levels, the Human Resources and
Governance Committee studies, among other things, the competitive market environment, and reviews information published in
the proxy circulars of other publicly listed biopharmaceutical and pharmaceutical companies having similar revenues, size and market
capitalization. The Human Resources and Governance Committee also takes into consideration the Company’s own financial targets
and past performance.

 

Elements
of Compensation Program, Determination of Amounts for each Elements, Rationale for Amounts of each Element

 

The major elements
of the Company’s executive compensation program are base salary, annual individual performance incentives (bonuses), and
long-term incentives through the granting of stock options and common shares in relation to incentive compensation agreements.
The Company’s executive compensation program aims at allocating 60% to incentive-based compensation and 40% to fixed remuneration.
The compensation policies and guidelines for the Named Executive Officers (as defined herein) and other senior executives, other
than the President and Chief Executive Officer, are recommended by the President and Chief Executive Officer and approved by the
Human Resources and Governance Committee. The compensation for the President and Chief Executive Officer is recommended by the
Human Resources and Governance Committee and approved by the Board.

 

Base
Salary 

 

Salaries for the
Named Executive Officers and other senior executives are based on the experience and expertise of each executive. In normal times,
the Company’s policy is for the total cash compensation of the Named Executive Officers and other senior executives, including
compensation under the bonus plan, generally to be aligned with the 50th percentile.

 

During the 2018 financial
year, the Human Resources and Governance Committee, with the assistance of the CEO and CFO, conducted an informal compensation
review of publicly available data relating to peer biotechnology companies of comparable revenues, size and market capitalization.
The Human Resources and Governance Committee compared the total compensation of the Named Executive Officers, including compensation
under the bonus plan, with that of the executive officers of the identified peer companies to assess

 

    	 	11	 

     

    

 

the reasonableness. The Company’s
identified peer companies consisted of the following: Acasti Pharma Inc., Aeterna Zentaris Inc., Aptose Biosciences Inc., Arbutus
BioPharma Corp., Fennec Pharmaceuticals Inc., IMV Inc., ProMIS Neurosciences Inc. and Xenon Pharmaceuticals Inc. (the “Peer
Group”). Based on its review, the Human Resources and Governance Committee concluded that the compensation of some of
the Named Executive Officers for 2018 was lower than those of the Peer Group. As such, in February 2019, the Board approved a 2019
base salary increase for François Desjardins, Vice President, Finance (12%) and Tony Matzouranis, Vice President, Business
Development (20%).

 

In February 2019,
the Board approved a salary adjustment for all employees, including the Named Executive Officers and other senior executives, taking
into consideration changes in the cost of living in the province of Québec and in Canada, as well as recent independent
compensation reports.

 

Performance
Reward Program (Bonus Plan)

 

The Bonus plan is
designed to recognize the contribution of the Named Executive Officers and the other senior executives to the Company’s key
strategies. Bonuses are granted in accordance with the individual performance and the results of the scientific projects. Each
senior executive of the Company is evaluated in the context of the annual performance review process. When and if the Company generates
significant revenues from the sale of its products, sales and profits will also factor into the determination of annual performance
bonuses, but such is not the case presently. The target bonus payment for Named Executive Officers (other than Mr. Bellini) is
set at twenty-five percent (25%) of base salary. For 2018, Mr. Bellini was eligible to receive a cash bonus equal to 50% of his
annual base salary, with the actual amount of the bonus paid depending upon the achievement of personal and corporate objectives
reasonably established by the Board. In February 2019, the Board approved that going forward Mr. Bellini would be eligible to receive
a cash bonus of up to 70% of his annual base salary, with the actual amount of the bonus paid depending upon the achievement of
personal and corporate objectives reasonably established by the Board. The corporate objectives consist of both financial and business
goals which are periodically reviewed by the Board.

 

Key Employee
Stock Options Plan

 

The Company believes
that the grant of stock options helps align management interest with the growth in shareholder value. In the past, senior executives
of the Company, including the Named Executive Officers, have been provided with incentive to (a) advance the Company’s drug
development programs towards commercialization and (b) enhance the market value of the Company’s Common Shares, through the
granting of stock options to purchase Common Shares.

 

The number of stock
options granted has been determined on the basis of the position of each senior executive. The Company allocates stock options
to the Named Executive Officers based on the following criteria:

 

		·	the then current market value of the underlying common
shares;

 

		·	the “Black-Scholes” value of the stock
options (as referred to herein);

 

		·	the number of stock options already granted to the
applicable Named Executive Officer;

 

		·	the exercise price of the previously granted stock
options; and

 

		·	whether and to what extent the grant will serve as
a reasonable “retention incentive” to the Named Executive Officer.

 

    	 	12	 

     

    

 

Option grants to
Named Executive Officers and other senior executives are proposed by the President and Chief Executive Officer to the Human Resources
and Governance Committee, which evaluates the proposal, including having regard to the number, vesting and exercise price of option
grants previously awarded to each individual, before making a recommendation to the Board. The Human Resources and Governance Committee
also reviews any changes proposed to the Plan under which option-based awards are granted before making a recommendation to the
Board in respect of any amendments to the Plan.

 

Performance Graph

 

The outstanding Common
Shares of the predecessor of the Company prior to the 2012 corporate reorganization began trading at the opening of business on
June 22, 2000, on the TSX. The outstanding Common Shares began trading on a post-consolidated basis at the opening of business
on May 29, 2012 on the TSX (BLU).

 

The following graph
compares, as at the end of each year up to December 31, 2018, the cumulative total shareholder return on $100 invested in
Common Shares on December 31, 2013, with the cumulative total shareholder return on the S&P/TSX Composite Index, assuming reinvestment
of all dividends.

 

 

 

The trend shown by
the above performance graph does not directly correlate to the compensation paid to the Named Executives Officers. The factors
considered by the Company’s Human Resources and Governance Committee and Board in determining compensation matters, such
as individual and company performance and demand for skilled professionals, may not be heavily influenced by the market price of
the Common Shares. The shareholder return realized on the Common Shares is affected by a number of different factors, including
the Company’s performance, general market conditions and economic conditions, some of which are discussed in the “Risk
Factors” section of the Company’s Annual Information Form dated March 13, 2019, accessible through SEDAR at www.sedar.com.
Many of these factors are beyond the control of the Company and the Named Executive Officers.

 

    	 	13	 

     

    

 

Summary Compensation Table

 

The following table
details the comparative compensation information for the three most recent financial years of the Company, for the Chief Executive
Officer, the Vice President, Finance and the two other most highly compensated executive officers of the Company during the most
recently completed fiscal year (collectively, the “Named Executive Officers”). The information includes the
basic salary, the bonuses granted, the number of stock options granted, as well as all other compensation paid that is not mentioned
elsewhere. This information has been provided with respect to the financial years ended December 31, 2018, December 31, 2017 and
December 31, 2016.

 

	
        Name and principal

        position
	Year	
        Salary 

        ($)
	
        Share-Based

        Awards 

        ($)
	
        Option-Based

        Awards 

        ($)
	
        Non-equity

        Incentive Plan

        Compensation –

        Annual Incentive

        Plan ($)
	
        Pension 

        Value 

        ($)
	
        All Other

        Compensation

        ($)
	
        Total

        Compensation

        ($)

	
        Roberto Bellini 

        President and Chief

        Executive Officer
        
	2018	$364,140	NIL	$425,312 (1)	$182,070 (2)	N/A	$30,207	$1,001,729
	2017	$318,325 (3)	NIL	$219,772(4)	$214,200 (5)	N/A	$29,850	$782,147
	2016	$357,000	NIL	NIL	NIL	N/A	$29,850	$386,850
	
        François Desjardins 

        Vice President, Finance 
	2018	$187,569 	NIL	$106,328 (1)	$46,892 (2)	N/A	$21,378	$362,167
	2017	$173,930 (3)	NIL	$64,639 (4)	$55,167 (5)	N/A	$21,195	$314,931
	2016	$183,891	NIL	NIL	NIL	N/A	$21,195	$205,086
	
        Denis Garceau

        Senior Vice President,

        Drug Development
	2018	$344,872 	NIL	$141,771 (1)	$86,218 (2)	N/A	$29,244	$602,105
	2017	$301,481 (3)	NIL	$77,566 (4)	$101,433 (5)	N/A	$28,906	$509,386
	2016	$338,110	NIL	NIL	$22,500	N/A	$28,906	$389,516
	
        Tony Matzouranis

        Vice President, Business

        Development 
	2018	$187,569 	NIL	$120,505 (1)	$46,892 (2)	N/A	$21,378	$376,344
	2017	$173,930 (3)	NIL	$77,566 (4)	$55,167 (5)	N/A	$21,195	$327,858
	2016	$183,891	NIL	NIL	NIL	N/A	$21,195	$205,086

 

		(1)	Stock options were granted on February 20, 2018, having
an exercise price of $0.35. In determining the fair value of the option awards, the Black-Scholes model, an established methodology,
was used, with the following weighted average assumptions:

		(i)	Risk-free
                                         interest rate: 2.19%;

		(ii)	Expected volatility in the market price of the shares:
99.92%;

		(iii)	Expected dividend yield: 0%; and

		(iv)	Expected life: 7 years.

Resulting
fair value per option: $0.284.

		(2)	This bonus was earned in 2018, but paid in cash in 2019.

		(3)	In 2017, the Name Executive Officers’ base salary
was temporarily reduced effective May 16, 2017. The temporary reduction ceased following the closing of the Company’s equity
offering in December 2017.

		(4)	Stock options were granted on March 23, 2017, having an
exercise price of $0.30. In determining the fair value of the option awards, the Black-Scholes model, an established methodology,
was used, with the following weighted average assumptions:

		(i)	Risk-free interest rate: 1.15%;

		(ii)	Expected volatility in the market price of the shares:
106.93%;

		(iii)	Expected dividend yield: 0%; and

		(iv)	Expected life: 7 years.

Resulting
fair value per option: $0.259.

		(5)	This bonus was earned in 2017, but paid in cash in 2018.

 

    	 	14	 

     

    

 

Incentive Plan Awards

 

Outstanding
Share-Based Awards and Option-Based Awards

 

The following table indicates for each
of the Named Executive Officers all awards outstanding at the end of the 2018 financial year.

 

	 	Option-based Awards	Share-based Awards
	Name	
        Number of

        Securities

        Underlying

        Unexercised 

        Stock Options or

        Shares

        (#)
	
        Stock

        Option or

        Share

        Exercise

        Price

        ($)
	
        Stock Option

        Expiration

        Date
	
        Value of

        Unexercised

        In-The-Money

        Stock Options (1) (2)

        ($)

         
	
        Number of Shares or

        Units of Shares

        That Have Not

        Vested (#) as at

        December 31, 2018

        (#)
	
        Markets or

        Payout Value of

        Shares-Based

        Awards That

        Have Not Vested

        ($)
	
        Markets or

        Payout Value of

        Vested Shares-

        Based Awards

        Not Paid Out or

        Distributed

        ($) (3)

	
        Roberto Bellini 

        President and Chief

        Executive Officer
	1,500,000	$0.35	February 20, 2028	$1,005,000	1,500,000	N/A	N/A
	850,000	$0.30	May 23, 2027	$612,000	680,000	N/A	N/A
	103,000	$1.12	February 24, 2026	NIL	61,800	N/A	N/A
	1,600,000	$0.50	August 24, 2022	$832,000	NIL	N/A	N/A
	89,750.3 (4)	N/A	N/A	N/A	N/A	N/A	$98,239
	
        François Desjardins 

        Vice President, Finance
	375,000	$0.35	February 20, 2028	$251,250	375,000	N/A	N/A
	250,000	$0.30	May 23, 2027	$180,000	200,000	N/A	N/A
	400,000	$0.50	August 24, 2022	$208,000	NIL	N/A	N/A
	2,146.2 (4)	N/A	N/A	N/A	N/A	N/A	$2,349
	
        Denis Garceau

        Senior Vice President,

        Drug Development
	500,000	$0.35	February 20, 2028	$335,000	500,000	N/A	N/A
	300,000	$0.30	May 23, 2027	$216,000	240,000	N/A	N/A
	550,000	$0.50	August 24, 2022	$286,000	NIL	N/A	N/A
	1,648.2 (4)	N/A	N/A	N/A	N/A	N/A	$1,804
	
        Tony Matzouranis

        Vice President, Business

        Development 
	425,000	$0.35	February 20, 2028	$284,750	425,000	N/A	N/A
	300,000	$0.30	May 23, 2027	$216,000	240,000	N/A	N/A
	400,000	$0.50	August 24, 2022	$208,000	NIL	N/A	N/A

 

		(1)	As at December 31, 2018, BELLUS Health Inc.’s closing
stock price on the TSX was $1.02.

		(2)	The value of the unexercised “in-the-money”
stock options is calculated using the closing stock price on the TSX as at December 31, 2018, less the respective exercise price
of the stock options. This value has not been, and may never be, realized. The actual gain, if any, will depend on the stock price
on the dates, if any, on which the stock options are exercised.

		(3)	Cash Value of DSUs
                                         as at December 31, 2018 is $1.0946 per unit.

		(4)	DSUs vest immediately on the grant date. DSUs are redeemable
only upon participant’s departure, until December 15 of the year following such departure.

 

Value Vested or Earned on Incentive Plan Awards During
the Most Recently Completed Fiscal Year

 

The following table indicates for each
of the Named Executive Officers the value on vesting of all awards and the bonus payout during the 2018 financial year.

 

	Name	
        Option Awards - Value Vested

        During the Year on Vesting

        ($)
	
        Share Awards - Value Vested

        During the Year on Vesting

        ($)
	
        Non-Equity Incentive Plan

        Compensation – Value

        Earned During the Year

        ($) (1)

	
        Roberto Bellini 

        President and Chief Executive Officer 
	$51,000	N/A	$182,070
	
        François Desjardins 

        Vice President, Finance
	$15,000	N/A	$46,892
	
        Denis Garceau

        Senior Vice President, Drug Development
	$18,000	N/A	$86,218
	
        Tony Matzouranis

        Vice President, Business Development
	$18,000	N/A	$46,892

 

		(1)	Corresponds to the same amounts as disclosed in the “Summary
Compensation Table” above.

 

    	 	15	 

     

    

 

Termination and Change of Control Benefits

 

In case of termination
in 2018, for reason other than for just cause or for good reason, and other than termination following a change of control
of the Company, Mr. Roberto Bellini, Mr. Francois Desjardins, Dr. Denis Garceau and Mr. Tony Matzouranis are entitled, under
their employment agreements, to lump sum payments of $394,347, $208,947, $374,116 and $208,947, respectively. Assuming termination
on December 31, 2018, lump sum payments of $394,347, $208,947, $374,116 and $208,947 would have been made to each of Mr. Roberto
Bellini, Mr. Francois Desjardins, Dr. Denis Garceau and Mr. Tony Matzouranis, respectively. Mr. Roberto Bellini, Mr. Francois Desjardins,
Dr. Denis Garceau and Mr. Tony Matzouranis would have realized $954,400, $244,000, $329,200 and $251,200, respectively, on the
exercise of vested stock options on December 31, 2018.

 

In case of termination
in 2018 of the employment within 6 months following a change of control of the Company, each of Mr. Roberto Bellini, Mr. Francois
Desjardins, Dr. Denis Garceau and Mr. Tony Matzouranis are entitled, under their employment agreements, to lump sum payments of
$394,347, $208,947, $374,116 and $208,947, respectively. Assuming termination on December 31, 2018, following a change in
control of the Company, lump sum payments of $394,347, $208,947, $374,116 and $208,947, would have been made to each of Mr. Roberto
Bellini, Mr. Francois Desjardins, Dr. Denis Garceau and Mr. Tony Matzouranis, respectively. A change of control of the Company
triggers the full vesting of all unvested stock options of the Company on an accelerated basis. Accordingly, Mr. Roberto Bellini,
Mr. Francois Desjardins, Dr. Denis Garceau and Mr. Tony Matzouranis would have realized $2,449,000, $639,250, $837,000 and $708,750,
respectively, on the exercise of stock options on December 31, 2018.

 

Compensation of Directors 

 

The members of the
Board of Directors are remunerated for services in their capacity as directors with cash compensation and stock options to acquire
Common Shares.

 

Compensation
of the members of the Board for the period from January 1 to February 20, 2018: The Chairman of the Board during this period
received an attendance fee of $1,500 per meeting of the Board. Additionally, directors who served on committees of the Board
were entitled to an attendance fee of $1,000 for every meeting of a Board committee.

 

Compensation
of the members of the Board for the period from February 20, 2018 to December 31, 2018: Non-executive members of the Board
during this period received an annual retainer fee of $45,000, with an additional retainer fee of $25,000 paid to the lead director.
Additionally, directors who served on committees of the Board were entitled to additional fees, as follows: an annual retainer
of $12,500 for the Chair of the Human Resources and Governance Committee, an annual retainer of $20,000 for the Chair of the Audit
Committee and an annual retainer of $7,500 for each other committee member. During the 2018 financial year, the Human Resources
and Governance Committee, with the assistance of the CEO and CFO, conducted a compensation review of publicly available data relating
to peer biotechnology companies of comparable revenues, size and market capitalization. The Human Resources and Governance Committee
compared the total compensation of the members of the Board of the Company with that of the members of the Board of the identified
peer companies to assess the reasonableness. The Company’s identified peer companies consisted of the following: Acasti Pharma
Inc., Aeterna Zentaris Inc., Aptose Biosciences Inc., Arbutus BioPharma Corp., Fennec Pharmaceuticals Inc., IMV Inc., ProMIS Neurosciences
Inc. and Xenon Pharmaceuticals Inc. (the “Peer Group”). Based on its review, the Human Resources and Governance
Committee concluded that the compensation of the members of the Board was reasonable for 2018.

 

    	 	16	 

     

    

 

Summary Compensation
Table for the financial year ended December 31, 2018: The following table provides details of the compensation of the non-executive
members of the Board during the financial year ended December 31, 2018.

 

	Name	
        Attendance

        Fees

        ($) (1)
	
        Annual Fees 

        ($) (2), (3)
	
        Share-Based

        Awards

        ($)
	
        Option-Based

        Awards

        ($)
	
        Non-Equity

        Incentive Plan

        Compensation 

        ($)
	
        Pension

        Value

        ($)
	
        All Other

        Compensation ($)
	
        Total

        ($)

	Dr. Francesco Bellini	$1,500	NIL	NIL	$70,885 (4)	N/A	N/A	$250,000 (5)	$322,385
	Dr. Youssef L. Bennani	$1,000	$52,500	NIL	$42,531 (4)	N/A	N/A	N/A	$96,031
	Franklin M. Berger	NIL	$52,500	NIL	$42,531 (4)	N/A	N/A	N/A	$95,031
	Dr. Clarissa Desjardins	NIL	$45,000	NIL	$42,531 (4)	N/A	N/A	N/A	$87,531
	Chau Q. Khuong (6)	NIL	$17,724	NIL	NIL	N/A	N/A	N/A	$17,724
	Pierre Larochelle	$1,000	$97,500	NIL	$42,531 (4)	N/A	N/A	N/A	$141,031
	Joseph Rus	$1,000	$65,000	NIL	$42,531 (4)	N/A	N/A	N/A	$108,531

 

		(1)	Attendance fees were paid under the compensation effective
from January 1 to February 20, 2018.

		(2)	The 2018 annual fees were paid in cash or in the form of
DSUs, at the director’s discretion. For directors who opted to receive DSUs, such DSUs were granted as follows:

 

	Name	Date of payment	DSU unit price	Nb. of units allocated
	Franklin M. Berger	May 31,2018	$0.5725	91,704
	Dr. Clarissa Desjardins	May 31,2018	$0.5725	78,603
	Chau Q. Khuong	January 11, 2019	$1.0457	16,950
	Pierre Larochelle	May 31,2018	$0.5725	170,306

 

		(3)	The fourth installment of the 2017 annual fees, included
in the 2017 compensation, was paid in cash or in the form of DSUs, at the director’s discretion, on March 15, 2018. For
directors who opted to receive DSUs, such DSUs were granted at a unit price of $0.4630 as follows:

 

	Name	Nb. of units allocated
	Dr. Clarissa Desjardins	24,299
	Pierre Larochelle	52,647
	Joseph Rus	17,549

 

		(4)	Stock options were granted on February 20, 2018, having
an exercise price of $0.35. In determining the fair value of the option awards, the Black-Scholes model, an established methodology,
was used, with the following weighted average assumptions:

		(i)	Risk-free interest rate: 2.19%;

		(ii)	Expected volatility in the market price of the shares:
99.92%;

		(iii)	Expected dividend yield: 0%; and

		(iv)	Expected life: 7 years.

Resulting
fair value per stock option: $0.284.

		(5)	The Company has entered into a Consulting and Service Agreement
with effect from January 1, 2010, with Picchio International providing for strategic advice on matters pertaining to the
development and commercialization of pharmaceutical products to provide health solutions to address critical unmet needs. See
 “Interest of Informed Persons in Material Transactions and Management Contracts – Consulting and Service Agreement”
in this Circular. This amount excludes reimbursement of reasonable expenses incurred in the proper conduct of the services as
per the agreement.

		(6)	Mr. Khuong was elected to the Board effective December
18, 2018.

 

    	 	17	 

     

    

 

Outstanding
Share-Based Awards and Option-Based Awards: The following table indicates all awards outstanding at the end of the 2018
financial year for each of the non-executive directors of the Company.

 

	 	Option-based Awards	Shares-based Awards
	Name	
        Number of

        Securities

        Underlying

        Unexercised

        Stock Options

        or Shares 

        (#)
	
        Stock

        Option or

        Share

        Exercise

        Price

        ($)
	
        Stock Option

        Expiration

        Date
	
        Value of

        Unexercised

        In-The-Money

        Stock Options

        ($) (1) (2)
	
        Number of Shares or

        Units of Shares

        That Have Not

        Vested

        as at December 31,

        2018

        (#)
	
        Markets or

        Payout Value

        of Shares-Based

        Awards That

        Have Not Vested

        ($)
	
        Markets or

        Payout Value of

        Vested Shares-Based

        Awards

        Not Paid Out or

        Distributed

        ($) (3)

	Dr. Francesco Bellini	250,000	$0.35	February 20, 2028	$167,500	250,000	N/A	N/A
	150,000	$0.30	May 23, 2027	$108,000	120,000	N/A	N/A
	270,000	$0.50	August 24, 2022	$140,400	NIL	N/A	N/A
	102,131.1 (4)	N/A	N/A	N/A	N/A	N/A	$111,791
	Dr. Youssef L. Bennani	150,000	$0.35	February 20, 2028	$100,500	150,000	N/A	N/A
	150,000	$0.30	May 23, 2027	$108,000	120,000	N/A	N/A
	Franklin M. Berger	150,000	$0.35	February 20, 2028	$100,500	150,000	N/A	N/A
	100,000	$0.30	May 23, 2027	$72,000	80,000	N/A	N/A
	150,000	$0.50	August 24, 2022	$78,000	NIL	N/A	N/A
	91,704 (4)	N/A	N/A	N/A	N/A	N/A	$100,377
	Dr. Clarissa Desjardins	150,000	$0.35	February 20, 2028	$100,500	150,000	N/A	N/A
	150,000	$0.42	November 7, 2027	$90,000	120,000	N/A	N/A
	102,902 (4)	N/A	N/A	N/A	N/A	N/A	$112,634
	Pierre Larochelle	150,000	$0.35	February 20, 2028	$100,500	150,000	N/A	N/A
	100,000	$0.30	May 23, 2027	$72,000	80,000	N/A	N/A
	150,000	$0.50	August 24, 2022	$78,000	NIL	N/A	N/A
	245,037.2 (4)	N/A	N/A	N/A	N/A	N/A	$268,213
	Joseph Rus	150,000	$0.35	February 20, 2028	$100,500	150,000	N/A	N/A
	100,000	$0.30	May 23, 2027	$72,000	80,000	N/A	N/A
	150,000	$0.50	August 24, 2022	$78,000	NIL	N/A	N/A
	17,549 (4)	N/A	N/A	N/A	N/A	N/A	$19,209

 

		(1)	As at December 31, 2018, BELLUS Health Inc.’s closing
stock price on the TSX was $1.02.

		(2)	The value of the unexercised “in-the-money”
stock options is calculated using the closing stock price on the TSX as at December 31, 2018, less the respective exercise price
of the stock options. This value has not been, and may never be, realized. The actual gain, if any, will depend on the stock price
on the dates, if any, on which the stock options are exercised.

		(3)	Cash Value of DSUs as at December 31, 2018 is $1.0946 per
unit.

		(4)	DSUs vest immediately on the grant date. DSUs are redeemable
only upon participant’s departure, until December 15 of the year following such departure.

 

    	 	18	 

     

    

 

Value vested or earned on incentive plan awards during
the most recently completed fiscal year:

 

The following table indicates for each
of the non-executive directors of the Company, the value on vesting of all awards during the 2018 financial year.

 

	Name	
        Option Awards - Value Vested

        During the Year on Vesting

        ($)
	
        Share Awards - Value Vested

        During the Year on Vesting

        ($)
	
        Non-Equity Incentive Plan

        Compensation - Value Earned During the
        Year

        ($)

	Dr. Francesco Bellini	$9,000	N/A	N/A
	Dr. Youssef L. Bennani	$9,000	N/A	N/A
	Franklin M. Berger	$6,000	N/A	N/A
	Dr. Clarissa Desjardins	$17,400	N/A	N/A
	Chau Q. Khuong	N/A	N/A	N/A
	Pierre Larochelle	$6,000	N/A	N/A
	Joseph Rus	$6,000	N/A	N/A

 

Compensation Governance

 

Among other things,
the Human Resources and Governance Committee is responsible for assisting the Board in discharging its oversight responsibilities
relating to human resources and executive compensation, including by assisting the Board in determining appropriate compensation
for the Company’s directors and executive officers.

 

The mandate of the
Human Resources and Governance Committee includes reviewing the compensation arrangements for the Company’s employees, including
executive officers and directors, and making recommendations to the Board with respect to such compensation arrangements, as well
as making recommendations to the Board with respect to the Company’s incentive compensation plans and equity-based plans
and overseeing succession planning. Moreover, the Human Resources and Governance Committee is responsible for reviewing and recommending
to the Board the levels of compensation of the CEO and the officers reporting to the CEO, as well as reviewing the objectives of
the CEO and assessing his performance in respect of such assessment. The Human Resources and Governance Committee is also responsible
for reviewing the adequacy and forms of compensation, director compensation and the review of the executive compensation disclosure
of the issuer.

 

The current members
of the Human Resources and Governance Committee are Mr. Joseph Rus (Chair), Mr. Pierre Larochelle and Dr. Youssef L. Bennani. Mr.
Joseph Rus, Mr. Pierre Larochelle and Dr. Youssef L. Bennani are all independent directors. The members of the Human Resources
and Governance Committee were selected according to their experience and their knowledge of matters to be dealt with by the Human
Resources and Governance Committee.

 

Each member of the
Human Resources and Governance Committee has direct experience that is relevant to his responsibilities in executive compensation,
as well as the skills and experience necessary to enable him to make decisions as to the suitability of the Company’s policies
and practices. More specifically, each committee member has held a number of executive management roles, in most cases as president
of companies, where the human resources department was reporting to them. In addition, each committee member has financial skills
relating to management compensation. In connection with their various responsibilities, all of these directors have also implemented
and managed compensation policies and practices, including with respect to wage policies, components of management compensation,
succession plans and share-based incentive programs.

 

The Board has adopted
a charter of the Human Resources and Governance Committee which clearly establishes the Human Resources and Governance Committee’s
purpose, responsibilities, member qualifications,

 

    	 	19	 

     

    

 

member appointment and removal, structure,
operations and manner of reporting to the Board. The charter also provides authority to the Human Resources and Governance Committee
to engage an outside advisor, if necessary.

 

No compensation consultant
or advisor was retained by the Company to assist the Human Resources and Governance Committee on any matters during the financial
year ended December 31, 2018.

 

The Human Resources
and Governance Committee reviews compensation policies and practices of the Company taking into account risks associated with these
policies and practices. The Human Resources and Governance Committee has not identified risks associated with the Company’s
compensation policies which could have material adverse consequences on the Company. The risks and uncertainties which may have
material adverse consequences on the Company are disclosed in the Company’s public filings, including the Company’s
Annual Information Form. None of these risks relates to compensation policies and practices of the Company.

 

Although the Company
has not adopted a policy forbidding Named Executive Officers and directors from purchasing financial instruments relating to the
Company’s shares, the Company is not aware of any insider having entered into this type of transaction.

 

Equity Compensation Plans

 

Stock Option Plan

 

The Company may grant,
under the Plan, together with any Common Shares reserved for issuance under any other security-based compensation arrangement,
up to 12.5% of the issued and outstanding Common Shares. As at March 13, 2019, the total number of Common Shares issued
under the Plan and issuable under outstanding stock options granted under the Plan and the percentage of the Company’s issued
and outstanding Common Shares represented by such shares, was as follows:

 

	
        Common Shares issued
        

        under the Plan
	
        Common Shares issuable

        under outstanding
        stock options

	NIL (0%)	15,238,000 (9.6%)

 

As at March 13,
2019, 4,506,522 stock options were available for grants under the Plan, representing approximately 2.9% of issued and outstanding
Common Shares as at such date.

 

The following table
outlines the burn rate for the Plan for the past three years as of December 31, 2018:

 

	Description	2018	2017	2016
	The burn rate is calculated by dividing the number of stock options granted under the Plan during a fiscal year, by the weighted average number of shares outstanding for the fiscal year	3.6%	4.2%	0.2%

 

Pursuant to the Plan,
stock options may be granted to directors, officers, employees, consultants and members of the Scientific Advisory Board (if any)
of the Company or any affiliate thereof, and the number of Common Shares subject to each stock option, the expiration date of each
stock option, the extent to which each stock option is exercisable from time to time during its term and other terms and conditions
relating to each such stock option shall be determined by the Human Resources and Governance Committee and be subject to approval
by the Board, provided, however, that if no specific determination is made by the Human Resources and Governance Committee with
respect to any of the foregoing matters, each stock option shall, subject to any other specific provisions of the Plan, contain
the following terms and conditions:

 

    	 	20	 

     

    

 

		(a)	the period during which a stock option shall be exercisable
shall be 10 years from the date of the grant; and

 

		(b)	the optionee may take up and pay for not more than
20% of the Common Shares covered by the stock option after the expiration of each one-year period in arrears from the date of
the grant; provided, however, that if the number of Common Shares taken up under the stock option after the expiration of each
one-year period is less than 20% of the Common Shares covered by the stock option, the optionee shall have the right, on a cumulative
basis, at any time or from time to time during the remainder of the term of the stock option, to purchase such number of Common
Shares subject to the stock options that were purchasable, but not purchased by such optionee, after the expiration of each such
one-year period.

 

The purchase price
for Common Shares granted under stock options is determined by the Human Resources and Governance Committee but shall not be less
than the volume weighted average trading price for such Common Shares for the five days preceding the effective date of grant during
which the Common Shares were traded on the TSX. In no event may the term of any stock option exceed 10 years from the date of the
grant of the stock option. A stock option is personal to the optionee and is non-assignable.

 

The Plan provides
for the following limitations on the number of Common Shares issuable thereunder:

 

		(a)	the aggregate number of Common Shares reserved for
issuance at any time to any one optionee shall not exceed 5% of the number of Common Shares of the Company outstanding on a non-diluted
basis at such time, less the total of all shares reserved for issuance to such optionee pursuant to any other share compensation
arrangement of the Company and its affiliates;

 

		(b)	the aggregate number of Common Shares issuable (or,
reserved for issuance) to insiders of the Company and its affiliates under the Plan and any other share compensation arrangement
of the Company and its affiliates, cannot at any time exceed 10% of the issued and outstanding Common Shares; and

 

		(c)	the aggregate number of Common Shares issued to insiders
under the Plan and any other share compensation arrangement of the Company and its affiliates, within a one-year period, cannot
exceed 10% of the issued and outstanding Common Shares.

 

Subject to any express
resolution passed by the Board or the Human Resources and Governance Committee with respect to a stock option, a stock option,
and all rights to purchase Common Shares pursuant thereto, shall expire and terminate immediately upon an optionee ceasing to be
a director, full-time employee, consultant or member of the Scientific Advisory Board of the Company and its affiliates. For greater
certainty, the optionee shall not lose any rights to any stock options granted pursuant to the Plan if he/she changes positions
within the Company and its affiliates so long as he/she remains eligible. If, before the expiry of a stock option, in accordance
with the terms thereof, the employment of the optionee by the Company and its affiliates terminates for any reason whatsoever other
than termination by the Company and its affiliates for cause, but including termination by reason of the death of the optionee,
such stock option may, subject to the terms thereof and any other terms of the Plan, be exercised, if the optionee is deceased,
by the legal personal representative(s) of the estate of the optionee during the first three months following the death of the
optionee, or if he/she is alive, by the optionee, at any time within three months of the date of termination of the employment
of the optionee (but in either case prior to the expiry of the option in accordance with the terms thereof), but only to the extent
that the optionee was entitled to exercise such stock option at the date of the termination of his employment.

 

Notwithstanding any
vesting period determined by the Board in respect of any stock option granted to an optionee at any time, the Board may, upon written
notice to all the optionees, provide that all or a portion of the then vested or unvested stock options held by such optionees
will become exercisable in full as of a specified time prior to the consummation of an Acquisition Event (as defined below) and
that all or a portion of the stock options (whether or not vested) will terminate immediately prior to the consummation of such
Acquisition Event,

 

    	 	21	 

     

    

 

except to the extent exercised by the
optionees before the consummation of such Acquisition Event; provided, however, that in the event of an Acquisition Event under
the terms of which holders of Common Shares will receive upon consummation thereof a cash payment for each Common Share surrendered
pursuant to such Acquisition Event (the “Acquisition Price”), then the Board may instead provide in such notice
that all or a portion of the outstanding vested or unvested (or both) stock options shall terminate upon consummation of such Acquisition
Event and that each optionee shall receive, in exchange therefore, a cash payment equal to the amount (if any) by which (A) the
Acquisition Price multiplied by the number of Common Shares subject to such outstanding stock options (whether or not then vested),
exceeds (B) the aggregate exercise price of such stock options. For the purposes thereof, “Acquisition Event” shall
mean any transaction or series of transactions after which a Person (or a related group of Persons) owns at least 50.1% of the
Common Shares; and “Person” shall mean any individual, corporation or company, partnership, joint venture, syndicate,
sole proprietorship, trust, trustee, executor, administrator or other legal representative or an unincorporated organization, government
or governmental authority or entity.

 

Notwithstanding anything
contained to the contrary in the Plan, or in any resolution of the Board in the implementation thereof, the Board may, by resolution,
and with the approval of the TSX, approve, at the election of optionees who cease to be directors of the Company upon application
of the mandatory retirement policy adopted by the Board from time to time, either:

 

		(a)	the acceleration of the date upon which any unvested
stock option may vest, and therefore be exercisable by such optionees, subject always to the three-month period for exercise set
forth in the Plan; or

 

		(b)	notwithstanding the three-month period for exercise
set forth in the Plan, the extension of the period for the exercise by such optionees of such stock options as are vested, and
therefore are exercisable by such optionees, on the date at which such optionee has ceased to be a director of the Company from
the three-month period for exercise set forth in the Plan to twelve months from the date at which any such optionee has ceased
to be a director of the Company.

 

The election referred
to above shall be made in writing to the Company no later than the date upon which such optionees cease to be directors of the
Company upon application of the mandatory retirement policy. The Board shall not, in the event of any such election, be under any
obligation to accelerate the date, or extend the exercise period, in accordance with which any stock option may be exercised by
any other optionee.

 

The Plan provides
that the Board may amend or discontinue the Plan at any time without notice or approval from the shareholders of the Company or
any optionee, for any purpose whatsoever, including, without limitation for the purpose of:

 

		(a)	amendments of a “housekeeping” nature,
which include, without limitation, amendments to ensure continued compliance with applicable laws, regulations, rules or policies
of any regulatory authority and amendments to remove any ambiguity or to correct or supplement any provision contained in the
Plan which may be incorrect or incompatible with any other provision of the Plan;

 

		(b)	a change to the vesting provisions of a stock option
of the Plan;

 

		(c)	a change to the termination provisions of a stock
option or the Plan which does not entail an extension beyond the original expiration date; and

 

		(d)	the addition of a cashless exercise feature payable
in cash or securities which provides for a full deduction of the number of underlying Common Shares from the number of Common
Shares reserved for issuance under the Plan;

 

    	 	22	 

     

    

 

provided, however, that no such amendment
may increase the maximum number of Common Shares issuable pursuant to the Plan, change the manner of determining the minimum Option
Price (as defined in the Plan), alter the stock option exercise period following the expiration of the Blackout Period (as defined
in the Plan) or, without the consent of the optionee, adversely alter or impair any stock option previously granted to an optionee
under the Plan.

 

The Plan also provides
that (i) a reduction in the Option Price, (ii) an extension of the expiration date of an outstanding stock option, (iii) any
amendment to the definition of “Eligible Person” under the Plan, or (iv) any amendment which would permit stock
options to be transferable or assignable other than for normal estate settlement purposes, may not be made without the approval
of the shareholders of the Company (excluding the votes of securities held directly or indirectly by insiders benefiting from the
amendment), provided that: (x) an adjustment to the Option Price pursuant to Article 9 of the Plan and (y) an extension
of the expiry date pursuant to Section 5.6 of the Plan, in each case subject to any applicable regulatory requirements, shall
not require approval of the shareholders of the Company.

 

The Plan provides
that if the term of a stock option of any eligible person under the Plan expires during or within 10 business days of the expiration
of a Blackout Period (as defined in the Plan), then the term of the stock option or the unexercised portion thereof, shall be extended
by 10 business days after the expiration of the Blackout Period.

 

The Plan also provides
that the Company may, from time to time, implement such procedures and conditions as it determines appropriate with respect to
the withholding and remittance of taxes imposed under applicable law, or the funding of related amounts for which liability may
arise under such applicable law. Without limiting the generality of the foregoing, following a stock option exercise, if the underlying
Common Shares issuable are not to be sold on the optionee’s behalf by the Company, the optionee must, in addition to following
the procedures set out elsewhere in the Plan, and as a condition of exercise: (i) deliver a certified cheque, wire transfer or
bank draft payable to the Company for the amount determined by the Company to be the appropriate amount on account of such taxes
or related amounts; or (ii) otherwise ensure, in a manner acceptable to the Company (if at all) in its sole and unfettered discretion,
that the amount will be securely funded; and must in all other respects follow any related procedures and conditions imposed by
the Company. In the event of an exercise pursuant to which Common Shares issuable to the optionee are to be sold on the optionee’s
behalf, the Company shall deduct from any proceeds payable to the optionee any and all amounts necessary to satisfy the Company’s
withholding and/or remittance obligations under applicable law.

 

The anti-dilution
provisions of the Plan adjust the exercise price and, in some cases, the amount of underlying shares that may be subscribed, in
the event of five (5) scenarios: (1) a reorganization of the share-capital; (2) an issuance of rights, stock options or warrants
to all or substantially all of the shareholders to subscribe for or purchase shares at a price per share that is less than 95%
of the market price per share; (3) a payment or issuance of a special dividend in cash or in kind; (4) an issuer bid where
the consideration per share exceeds the market price per share; and (5) other events affecting the shareholders where an optionee
has exercised his/her stock options after the effective date of such event.

 

Deferred Share Unit Plans

 

Effective January
1, 2007, the Company adopted a deferred share unit plan for directors and a deferred share unit plan for designated employees (the
 “DSU Plans”) pursuant to which members of the Board may, on an annual basis, elect to receive 100% of their
Board retainer in the form of DSUs and designated employees may elect to receive all or any part of their annual bonus in the form
of DSUs. The DSUs are redeemable once a Board member is no longer a member of the Board or a designated employee no longer employed
by the Company, and vest immediately upon being granted to such persons. Upon redemption, the value of the DSUs credited to a Board
member or designated employee will be based on the value of the Common Shares as at that

 

    	 	23	 

     

    

 

date, as adjusted pursuant to the terms
of the DSU Plans, and will be payable to such Board member or designated employee in a lump sum cash payment, subject to applicable
withholding taxes.

 

On December 31, 2018,
each DSU had a cash value of $1.0946.

 

Securities Authorized for Issuance
under Equity Compensation Plans

 

The following table
indicates the number of Common Shares to be issued upon the exercise of stock options outstanding as at March 13, 2019, the weighted
average exercise price of such outstanding stock options and the number of Common Shares remaining for future issuance under the
Plan.

 

	

Plan Category	
        Number of Common Shares to be

        issued upon exercise of 

        outstanding stock options
	
        Weighted-average exercise

        price of outstanding stock

        options 

        ($)
	
        Number of Common Shares

        remaining available for future

        issuance under equity compensation

        plans (excluding securities reflected

        in the first column)

	Equity compensation plans approved by security holders	15,238,000	$0.60	4,506,522
	Equity compensation plans not approved by security holders	N/A	N/A	N/A
	Total	15,238,000	$0.60	4,506,522

 

Indebtedness of Directors and Executive
Officers

 

No officers, directors,
employees or former officers, directors and employees of the Company were indebted to the Company as at March 13, 2019.

 

PART
4.

REPORT
ON CORPORATE GOVERNANCE AND OTHER ITEMS

 

“Corporate
governance” is the process and structure used to direct and manage the business and affairs of the Company to achieve the
shareholders’ objectives. The CSA has adopted National Policy 58-201 – Corporate Governance Guidelines (the “Guidelines”)
to provide guidance to Canadian reporting issuers regarding corporate governance. The Guidelines relate to a number of significant
governance issues, including the proper role of the board of directors, its structure and composition and its relationship with
shareholders and management. The CSA has also adopted National Instrument 58-101 – Disclosure of Corporate Governance Practices
requiring that disclosure be made by a listed corporation of its corporate governance practices. A complete description of the
Company’s corporate governance practices, with specific references to each of the Guidelines, is attached hereto as Schedule “B”.
The Human Resources and Governance Committee, currently composed of Mr. Joseph Rus (Chair), Mr. Pierre Larochelle and Dr. Youssef
L. Bennani, has reviewed the disclosure set out in Schedule “B”.

 

The Human Resources
and Governance Committee continues to periodically review corporate governance proposals made by the CSA. As new standards become
effective, the Human Resources and Governance Committee will review and amend, where necessary and appropriate, its corporate governance
practices and the eligibility of the members of the Board on each committee and shall, if necessary, make appropriate changes.

 

The following is
a description of the current committees of the Board:

 

Committees of the Board

 

Audit
Committee

 

The mandate of the
Audit Committee includes assisting the Board in its oversight of (i) the integrity of the Company’s financial statements,
accounting and financial reporting processes, system of internal controls over

 

    	 	24	 

     

    

 

financial reporting
and audit process, (ii) the Company’s compliance with, and process for monitoring compliance with, legal and regulatory
requirements so far as they may relate to matters of financial reporting, (iii) the independent auditors’ qualifications,
independence and performance, and (iv) the performance of the Company’s internal audit function (if any). The current
members of the Audit Committee are Mr. Pierre Larochelle (Chair), Mr. Franklin M. Berger and Mr. Joseph Rus.

 

Additional information
regarding the Audit Committee can be found under the heading “Audit Committee” in the Company’s Annual Information
Form for the year ended December 31, 2018 (the “Annual Information Form”).

 

Human
Resources and Governance Committee

 

Compensation Matters:
The mandate of the Human Resources and Governance Committee includes reviewing the compensation arrangements for the Company’s
employees, including executive officers and directors, and making recommendations to the Board with respect to such compensation
arrangements, as well as making recommendations to the Board with respect to the Company’s incentive compensation plans and
equity-based plans and overseeing succession planning.

 

Governance Matters:
The mandate of the Human Resources and Governance Committee is also to develop and recommend to the Board a set of corporate governance
principles and to prepare and review the disclosure with respect to, and the operation of, the Company’s system of corporate
governance, before such disclosure is submitted to the Board for its approval. The Human Resources and Governance Committee is
responsible for the review and periodic update of the Company’s corporate governance mandates, charters, policies and procedures,
including its Code of Ethics which governs the conduct of the Company’s directors, officers and other employees. Moreover,
the Human Resources and Governance Committee is mandated to examine, on an annual basis, the size and composition of the Board
and, if appropriate, recommend to the Board a program to establish a Board comprised of members who facilitate effective decision-making.

 

Human Resources
Matters: Finally, the Human Resources and Governance Committee shall also identify individuals qualified to become members
of the Board, recommend to the Board nominees to be put before shareholders at each annual meeting and recommend to the Board a
process for board, committee and director assessment. In fulfilling its responsibilities to identify nominees to the Board, the
Human Resources and Governance Committee comes up with the names of individuals it believes represent potentially suitable candidates
and also solicits names of other potentially suitable candidates from the other members of the Board of Directors and also from
management of the Company. It then looks at the qualifications and qualities of each in light of the needs of the Board of Directors
and the Company and bases its recommendation to the Board on this basis.

 

The current members
of the Human Resources and Governance Committee are Mr. Joseph Rus (Chair), Mr. Pierre Larochelle and Dr. Youssef L. Bennani.

 

Communications,
Insider Trading, Confidential Information and Disclosure Policies

 

The Board is committed
to an effective communications policy with all stakeholders including shareholders, suppliers, advertisers, employees, agents and
members of the investment community. The Company is committed to complying with all laws, regulations and policies which are applicable
to it, as well as to best practices in the field. This commitment is evidenced, notably, by the adoption by the Company of a Disclosure
and Trading Policy.

 

The Audit Committee
or the Board reviews in advance all press releases which disclose financial results. Other continuous disclosure documents, including,
without limitation, the annual report, proxy materials and Annual Information Form are reviewed by members of the Company’s
Disclosure Committee and, where appropriate, the Board and, where required, these documents are also approved by the Board.

 

    	 	25	 

     

    

 

Interest of Informed Persons In Material
Transactions and Management Contracts

 

Consulting and Service Agreement 

 

The Company has entered
into a Consulting and Service Agreement with effect from January 1, 2010, with Picchio International providing for strategic advice
on matters pertaining to the development and commercialization of pharmaceutical products to provide health solutions to address
critical unmet needs. Under the terms of that agreement Picchio International has assigned primary responsibility for providing
such services to Dr. Francesco Bellini. For the services, monthly fees of $20,833, plus applicable taxes, are paid, and Picchio
International is reimbursed for its reasonable expenses incurred in the proper conduct of the services. The Consulting and Services
Agreement automatically renews for successive one-year terms, unless one party advises the other party of its intention not to
renew by October 1 of the current year. During the fiscal period ended December 31, 2018, Picchio International received an
aggregate amount of $381,000 under the Consulting and Services Agreement.

 

The Consulting and
Services Agreement was automatically renewed for a one-year period, commencing on January 1, 2019.

 

2019 Shareholder Proposals

 

Shareholder proposals
must be submitted no later than December 14, 2019, to be considered for inclusion in the Management Information Circular for the
purposes of the Company’s 2020 annual meeting of shareholders.

 

Additional Information

 

Financial information
is provided in the Company’s audited financial statements and management's discussion and analysis for its most recently
completed financial year. Copies of these documents and additional information relating to the Company are available on SEDAR at
www.sedar.com.

 

Approval by Directors

 

The contents of the
Circular and the sending thereof have been approved by resolution of the Board.

 

DATED at Montréal,
Québec, Canada, March 13, 2019.

 

	 	 
	 	(signed) Sébastien Roy
	 	Corporate Secretary

 

    	 	26	 

     

    

 

SCHEDULE “A”

 

SHARE CONSOLIDATION RESOLUTION

 

be
and it is hereby resolved, as a special resolution that:

 

		1.	pursuant to the Canada Business Corporations Act
(the “CBCA”), the articles of BELLUS Health Inc. (the “Company”) be amended to consolidate
all of the issued and outstanding common shares (the “Common Shares”), such that the trading price of the post-consolidation
Common Shares is between US$5.00 and US$7.50 per post-consolidation Common Share calculated based on the five-day volume weighted
average trading price of the Common Shares, effective as at the discretion of the board of directors of the Company (the “Board”);

 

		2.	the Board be and is hereby authorized to revoke, without
further approval of the shareholders, this special resolution at any time prior to the completion thereof, notwithstanding the
approval by the shareholders of same, if determined, in the Board’s sole discretion to be in the best interest of the Company;
and

 

		3.	any director or officer of the Company is hereby authorized to execute or cause to be executed
and to deliver or cause to be delivered, all such certificates, instruments, agreements, notices and other documents and to do
or cause to be done all such other acts and things as such director or officer may determine to be necessary or desirable in order
to carry out the intent of this resolution, including but not limited to, the filing of articles of amendment under the CBCA, such
determination to be conclusively evidenced by the execution and delivery of such documents and other instruments or the doing of
any such act or thing.

 

    	 	A-1	 

     

    

 

SCHEDULE “B”

 

CORPORATE GOVERNANCE PRACTICES

 

This Schedule provides a detailed comparison
of the Company’s governance practices with the Guidelines. All capitalized terms used but not defined in this Schedule
shall have the meanings ascribed thereto in the Circular.

 

	
        Governance Disclosure Guideline

        under
        NI 58-101
	The Company’s Governance Procedures
	A.     Directors
	1. The board should have a majority of independent directors.	The Board currently consists of a majority of independent directors as, of the eight directors currently serving on the Board, six are considered independent, namely Dr. Youssef L. Bennani, Mr. Franklin M. Berger, CFA, Dr. Clarissa Desjardins, Mr. Chau Q. Khuong, Mr. Pierre Larochelle and Mr. Joseph Rus. Dr. Francesco Bellini, O.C. and Mr. Roberto Bellini are not independent directors. 
	
        Pursuant to the 2009 Board Representation
        Agreements, each of VSVI and Rocabe is entitled to cause up to two nominees to be included in the list of management nominees to
        be proposed for election to the Board at each shareholders’ meeting occurring following the date thereof. Mr. Larochelle
        is the nominee of VSVI and Dr. F. Bellini is the nominee of Rocabe. See “Election of Directors” on pages 6 and 7 of
        the Circular.

         

        Pursuant to the 2018 Board Representation
        Agreement, OrbiMed is entitled to cause one nominee to be included in the list of management nominees to be proposed for election
        to the Board at each shareholders’ meeting occurring following the date thereof. Mr. Chau Q. Khuong is the nominee of OrbiMed.
        See “Election of Directors” on pages 6 and 7 of the Circular.

         

        During the year ended December 31, 2018,
        Dr. Francesco Bellini, O.C., Chairman of the Board was not an independent director because of his relationship with Mr. Roberto
        Bellini, the current Chief Executive Officer (the “CEO”). Mr. Roberto Bellini was not independent because,
        as CEO, he is a member of the management of the Company.

         

        Regarding the persons proposed by management
        to be nominated for election as directors at the Meeting, a majority are considered independent. The nominees considered independent
        are: Dr. Youssef L. Bennani, Mr. Franklin M. Berger, CFA, Dr. Clarissa Desjardins, Mr. Chau Q. Khuong, Mr. Pierre

 

    	 	B-1	 

     

    

 

	
        Governance Disclosure Guideline

        under
        NI 58-101
	The Company’s Governance Procedures
	 	Larochelle and Mr. Joseph Rus. Dr. Francesco Bellini, O.C., the Chair of the Board of Directors, is not an independent director because of his relationship with Mr. Roberto Bellini, the current CEO. Mr. Roberto Bellini, the current CEO, is not an independent director as he is a member of the management of the Company.
	2. If a director is presently a director of any other reporting issuer, identify both the director and the other issuer.	A table identifying which directors are also directors of other reporting issuers is included on page 9 of the Circular.
	3. The Chair of the board should be an independent director.	
        The Chair of the Board, Dr. Francesco Bellini,
        O.C., is not an independent director. Given its current stage of development and the controls in place, the Board is of the
        opinion that it is in the best interests of the Company and its shareholders to have Dr. Francesco Bellini, O.C., continue
        to act as Chair of the Board.

         

        Mr. Pierre Larochelle acts as lead director.
        The lead director is the representative of the independent directors to the Board. He provides leadership to ensure that the Board’s
        agenda will enable it to successfully carry out its duties and leads meetings of the independent directors, as described below.

	4. The independent directors should hold regularly scheduled meetings at which non-independent directors and members of management are not in attendance.	The independent directors hold regular meetings at which non-independent directors and members of management are not in attendance, usually after regularly scheduled meetings of the Board. A record of attendance of each independent director at such meetings held in the fiscal year ended December 31, 2018, is included on page 8 of the Circular.
	5. The attendance record of each director for all board meetings held since the beginning of the issuer’s most recently completed financial year should be disclosed.	A record of attendance of each director at Board and Board Committee meetings held since the beginning of the Company’s most recently completed financial year is included on page 8 of the Circular.
	B.     Mandate of the Board of Directors
	6. The board should adopt a written mandate in which it explicitly acknowledges responsibility for the stewardship of the issuer.	The Board has explicitly assumed responsibility for the stewardship of the Company in a formal Mandate of the Board of Directors, which was revised and reconfirmed in February 2010. This Mandate is regularly reviewed and is attached herewith as Schedule “C”.
	C.      Position Descriptions
	7. The board should develop clear position descriptions for the Chair of the board and the Chair of each board committee. In addition, the board should develop a clear position 	The Board of Directors has adopted Terms of Reference for its Chair, for its lead director, for the Chair of the Audit Committee, for the Chair of the Human Resources and Governance Committee as 

 

    	 	B-2	 

     

    

 

	
        Governance Disclosure Guideline

        under
        NI 58-101
	The Company’s Governance Procedures
	description for the president and CEO. The board should also develop or approve the goals and objectives that the president and CEO must meet.	well as for the CEO. The Mandate of the Board of Directors, along with the charters of the committees, set forth the roles and responsibilities of the Board of Directors and its committees and guide the Chair of the Board and the Chairs of each committee in discharging their own responsibilities. The Board of Directors also periodically discusses with the CEO his role and responsibilities, as well as his goals and objectives.
	D.     Orientation and Continuing Education
	
        8. The board should ensure that all
        new directors receive a comprehensive orientation. All new directors should understand the nature and operation of the issuer’s
        business.

         

        The board should provide continuing education
        opportunities for all directors.
	
        The Human Resources and Governance Committee
        has the mandate, explicitly documented in its Charter, to consider the appropriateness of implementing, from time to time and as
        appropriate, orientation and continuing education for directors.

         

        Directors receive comprehensive packages
        prior to each Board and committee meeting, and are regularly briefed by management on the business and activities of the Company.

         

        Further, the directors also receive a comprehensive
        binder setting out all of the Company’s corporate governance mandates, charters, policies, practices and procedures, together
        with copies of relevant legislation and regulations, and informational updates and analyses provided to the public by external
        legal advisors relating to corporate governance matters. This binder is updated periodically, as necessary.

         

        The directors have discussed with management
        the development of a program of continuing education on the Company’s ongoing development programs aimed at helping each
        director participate actively in decisions relating to the Company’s ongoing and future development programs. In light thereof,
        the Company’s management provides regular briefings to the Board regarding the Company’s ongoing development programs.

	E.     Ethical Business Conduct
	9. The board should adopt a written code of business conduct and ethics. The code should be applicable to directors, officers and employees of the issuer.	The Company has adopted a written code of ethics. This code is available through SEDAR at www.sedar.com. All directors, officers and employees of the Company are provided with a copy of the code of ethics.
	10. The board should be responsible for monitoring compliance with the code. Any waivers from the code that are granted for the benefit of the issuer’s directors or executive officers should be granted by the board (or a 	The Human Resources and Governance Committee is responsible for monitoring compliance with the Company's code of ethics. The Board has not granted any waiver from the code of ethics in favour of any director or executive officer of the Company in the 

 

    	 	B-3	 

     

    

 

	
        Governance Disclosure Guideline

        under
        NI 58-101
	The Company’s Governance Procedures
	board committee) only.	fiscal year ended December 31, 2018.
	11. The board must ensure that directors exercise independent judgment in considering transactions and agreements in which a director or executive officer has a material interest.	
        The code of ethics of the Company provides
        that each director, officer or employee, including in particular senior financial officers, (collectively the “Designated
        Individuals”) of the Company and its subsidiary must avoid any conflict, or perception of conflict, between his or her
        personal interests and the interests of the Company in transacting the Company’s business. All actions and decisions by Designated
        Individuals in the performance of work must be based on impartial and objective assessments of the Company’s interests in
        the situation, totally without regard to any gifts, favours, or similar benefits from outside parties that could affect (or be
        seen by others to possibly affect) their judgment. Any gift, loan to or guarantee of obligation of, or benefit of any kind that
        has a value in excess of $400 must be approved by the Vice President, Finance or, in his absence, the President and Chief Executive
        Officer the Company.

         

        The code of ethics also provides that no
        Designated Individual shall have any financial interest or position with any entity that transacts business with or competes with
        the Company other than the ownership of a minor percentage of shares in a public company without immediately disclosing these interests
        and obtaining the approval of the Vice President, Finance or, in the case of directors or officers, the Board.

	12. The board must take steps to encourage and promote a culture of ethical business conduct.	The Board is committed to encouraging and promoting a culture of ethical business conduct and integrity throughout the Company. In order to achieve this objective, and in addition to the implementation, monitoring and enforcement of the Company’s code of ethics, the Board has adopted an anonymous complaints procedure for accounting, auditing and scientific matters to ensure that there will be no retaliation against Designated Individuals who have complaints in these respects.
	F.      Nomination of Directors
	13. The board should appoint a nominating committee composed entirely of independent directors.	The Human Resources and Governance Committee is responsible for identifying nominees to the Board for election as directors. The Human Resources and Governance Committee is composed entirely of independent directors. In fulfilling its responsibilities to identify nominees to the Board, the Human Resources and Governance Committee comes up with the names of individuals it believes represent potentially suitable candidates and also solicits names of other potentially suitable candidates from the other 

 

    	 	B-4	 

     

    

 

	
        Governance Disclosure Guideline

        under
        NI 58-101
	The Company’s Governance Procedures
	 	members of the Board of Directors and also from management of the Company. It then looks at the qualifications and qualities of each in light of the needs of the Board of Directors and the Company and bases its recommendation to the Board on this basis.
	14. The nominating committee should have a written charter that clearly establishes the committee’s purpose, responsibilities, member qualifications, member appointment and removal, structure, operations and manner of reporting to the board. In addition, the nominating committee should be given authority to engage and compensate any outside advisor that it determines to be necessary to permit it to carry out its duties.	The Board has adopted a charter of the Human Resources and Governance Committee which clearly establishes the Human Resources and Governance Committee’s purpose, responsibilities, member qualifications, member appointment and removal, structure, operations and manner of reporting to the Board. The charter also provides authority to the Human Resources and Governance Committee to engage outside advisors, if necessary.
	15. Prior to nominating or appointing individuals as directors, the board should adopt a process involving the following steps: consider what competencies and skills the board, as a whole, should possess and assess what competencies and skills each existing director possesses.	
        The Board is composed of directors with
        a variety of backgrounds, skills and experience. The Human Resources and Governance Committee is responsible for identifying and
        recommending to the Board individuals qualified to become board members.

         

        From time to time and as appropriate, the
        Human Resources and Governance Committee reviews the credentials of nominees to the Board, and assesses the existing strengths
        of the Board as well as the changing needs of the Company, to determine whether changes may be required to the composition of the
        Board to add value to the Company. The former Nominating and Corporate Governance Committee, which merged into the Human Resources
        and Governance Committee in 2017, undertook the most recent evaluation of the performance and effectiveness of the Board through
        an evaluation and discussions in March 2015.

	16. The board should consider the appropriate size of the board, with a view to facilitating effective decision-making by the board.	The Board presently consists of eight directors with a variety of backgrounds. Its size and composition are subject to periodic review of the Human Resources and Governance Committee. 
	17. The nominating committee should be responsible for identifying individuals qualified to become new board members and recommending to the board the new director nominees for the next annual meeting of shareholders.	The Human Resources and Governance Committee is responsible for identifying and recommending to the Board new candidates for election and for filling director vacancies.
	18. In making its recommendations, the nominating committee should consider the competencies and skills that the board considers to be necessary for the board, as a whole, to possess and those that the board 	As described above, the Human Resources and Governance Committee ensures that the composition of the Board is such that the required competencies and skills are represented on the Board and that the nominees make up a competent team which can carry 

 

    	 	B-5	 

     

    

 

	
        Governance Disclosure Guideline

        under
        NI 58-101
	The Company’s Governance Procedures
	considers each existing director and new nominee to possess.	out the Mandate of the Board and add value to the Company.
	19. The board should consider the representation of women on the board and in executive positions.	The Board is mindful of diversity within its ranks and in executive positions. While the Board has not, at this stage, considering its size and stage of development, adopted a written diversity policy or set a target number of women directors or executive officers, the Board and the Company do seek to include gender diversity within their ranks and consider the representation of women in the identification and selection of directors and executive officers; experience and expertise, at this stage of development of the Company, are the key elements, however, in the identification and the selection of directors and executive officers. One of the eight (13%) proposed nominees to the Board is a woman. The Company has four full-time executive officers, none of which is a woman; however, the Company has historically had a number of women executives in its ranks.
	G.Compensation
	20. The board should appoint a compensation committee composed entirely of independent directors.	The Human Resources and Governance Committee is responsible for assisting the Board in discharging its oversight responsibilities relating to, among other things, executive compensation. The Human Resources and Governance Committee is composed entirely of independent directors. 
	21. The compensation committee should have a written charter that establishes the committee’s purpose, responsibilities, member qualifications, member appointment and removal, structure, operations and the manner of reporting to the board. In addition, the compensation committee should be given authority to engage and compensate any outside advisor that it determines to be necessary to permit it to carry out its duties.	The Board has adopted a charter of the Human Resources and Governance Committee which clearly establishes its purpose, responsibilities, member qualifications, member appointment and removal, structure, operations and manner of reporting to the Board. The charter also provides authority to the Human Resources and Governance Committee to engage outside advisors, if necessary. 
	22. The compensation committee should be responsible for: reviewing and approving corporate goals and objectives relevant to CEO compensation, evaluating the CEO’s performance in light of those corporate goals and objectives, and determining (or making recommendations to the board with respect to) the CEO’s compensation level based on this evaluation; making recommendations to the board with respect to non-CEO officer and director compensation, incentive-compensation plans and equity-based plans 	The Human Resources and Governance Committee is responsible for reviewing and recommending to the Board the levels of compensation of the CEO and the officers reporting to the CEO, as well as reviewing the objectives of the CEO and assessing his performance in respect of such assessment. The Human Resources and Governance Committee is also responsible for reviewing the adequacy and forms of compensation, director compensation and the review of the executive compensation disclosure of the issuer. 

 

    	 	B-6	 

     

    

 

	
        Governance Disclosure Guideline

        under
        NI 58-101
	The Company’s Governance Procedures
	and reviewing executive compensation disclosure before the issuer publicly discloses this information.	 
	23. If a compensation consultant or advisor has, at any time since the beginning of the issuer’s most recently completed financial year, been retained to assist in determining compensation for any of the issuer’s directors and officers, disclose the identity of the consultant or advisor and briefly summarize the mandate for which they have been retained. If the consultant or advisor has been retained to perform any other work for the issuer, state that fact and briefly describe the nature of the work.	No compensation consultant or advisor was retained by the Company to assist the Human Resources and Governance Committee or the former Compensation Committee on any matters during the financial year ended December 31, 2018.
	H.    Other Board Committees
	24. Identify the standing committees of the board other than the audit, nominating and compensation committees, and describe their function.	The Board has no standing committees other than the Audit Committee and the Human Resources and Governance Committee described in detail on pages 24 and 25 of the Circular. 
	I.    Assessments
	25. The board, its committees and each individual director should be regularly assessed regarding his, her or its effectiveness and contribution.	
        The Human Resources and Governance Committee
        has the mandate, explicitly documented in its charter, to implement a process for assessing the effectiveness of the Board, its
        committees and individual directors.

         

        Directors aim to conduct an annual evaluation
        of the performance and effectiveness of the Board as a whole, in light of its Mandate. This evaluation is performed through peer
        review, evaluation and discussions amongst the directors. The most recent evaluation was conducted by the former Nominating and
        Corporate Governance Committee in March 2015.

	J.     Term Limits
	26. Disclose whether term limits for directors or other mechanisms of board renewal has been adopted.	The Board has not adopted formal term limits, as it is of the view that, at this stage of development, it is critical for the Board to ensure that the required competencies and skills continue to be represented within its ranks. The Human Resources and Governance Committee considers renewal of Board membership on a yearly basis.

 

    	 	B-7	 

     

    

 

SCHEDULE “C”

 

BELLUS HEALTH INC.

 

BOARD OF DIRECTORS MANDATE

 

		1.	MANDATE

 

		1.1	In
adopting this mandate,

 

		1.1.1	the board acknowledges that the mandate prescribed for it by the Canada Business Corporations
Act (the “CBCA”) is to manage, or supervise the management of, the business and affairs of BELLUS Health Inc. (the
 “Company”) and that this mandate includes responsibility for stewardship of the Company; and

 

		1.1.2	the board explicitly assumes responsibility for the stewardship of the Company, as contemplated
by the corporate governance guidelines adopted by the Canadian securities regulatory authorities (the “Canadian Guidelines”).

 

		2.	Board MEMBERSHIP

 

2.1                    Number of Members – The board shall consist of such number of directors as the board may determine from time to time,
provided that such number shall be within the minimum and maximum number of directors set out in the Company’s articles.

 

		2.2	Independence of Members –

 

		2.2.1	At least three of the directors shall not be officers or employees of the Company or any
of its affiliates.

 

		2.2.2	At least one-quarter of the directors shall be resident Canadians.

 

		2.2.3	As a goal, a majority of the directors should be independent as defined under the Canadian
Guidelines.

 

2.3                    Election and Appointment of Directors – Directors shall be elected by the shareholders at each annual meeting of
shareholders, provided that if directors are not elected at any annual meeting, the incumbent directors continue in office until
their successors are elected.

 

2.4                    Vacancy – The board may appoint a member to fill a vacancy, which occurs in the board between annual elections of
directors to the extent permitted by the CBCA.

 

2.5                    Removal of Members – Any director may be removed from office by an ordinary resolution of the shareholders at a special
meeting of shareholders.

 

2.6                    Additional
Directors – In addition to filling vacancies on the board, the directors may at any time, without exceeding the number
of directors provided by the articles of the Company, appoint one or more additional directors who shall hold office for a term
expiring not later than the close of the next annual meeting of shareholders, provided that the total number of directors so

 

    	 	C-1	 

     

    

 

appointed
may not exceed one-third (1/3) of the number of directors elected at the previous annual meetings of shareholders.

 

		3.	Board CHAIR

 

3.1                    Chairperson of the Board – The chairperson of the board shall, to the extent practicable, be independent within the
meaning of the Canadian Guidelines.

 

3.2                    Chairperson of Meetings – The chairperson of any meeting of the board shall be the first mentioned of such of the
following officers as have been appointed and who is a director and is present at the meeting: chairperson of the board, the deputy
chairperson, or chairperson of the executive committee of the board (if such a committee is constituted). If no such officer is
present, the directors present shall choose one of their number to be chairperson.

 

		4.	Meetings of the Board

 

4.1                    Quorum – Unless otherwise fixed by resolution of the directors, a quorum of the board shall be
a majority of its members.

 

4.2                    Secretary – The secretary of the board shall be designated from time to time in accordance with the by-laws of the
Company.

 

4.3                    Time and Place of Meetings – Meetings of the board shall be held from time to time and at such place as the board,
the deputy chairperson, the chairperson of the board, the chairperson of the executive committee of the board (if such a committee
is constituted) or any two directors may determine.

 

4.4                    Right to Vote – Each member of the board shall have the right to vote on matters that come before the board unless
precluded by the CBCA.

 

4.5                    Invitees – The board may invite officers and employees of the Company or any other person to attend meetings of the
board to assist in the discussion and examination of the matters under consideration by the board.

 

4.6                    Meeting of Independent Directors – The independent directors must hold regularly scheduled meetings at which only
independent directors are present.

 

4.7                    Attendance and Preparedness – Directors are expected to attend regularly scheduled meetings of the board and of the
shareholders and to have prepared for the meetings by, at a minimum, reviewing in advance of the meeting the materials delivered
in connection with the meeting. The attendance record of individual directors at meetings of the board will be disclosed in the
Company’s proxy circular as required by applicable law.

 

		5.	OUTSIDE ADVISORS

 

5.1                    Retaining and Compensating Advisors – Each director shall have the authority to retain outside counsel and any other
external advisors as appropriate with the approval of the Human Resources and Governance Committee.

 

    	 	C-2	 

     

    

 

		6.	Remuneration of Board Members

 

6.1                   Members of the board shall receive such remuneration for their service on the board and its committees as the board may determine
from time to time.

 

		7.	duties and responsibilities of the board

 

7.1                   Specific Aspects of Stewardship Function – In adopting this mandate, the board hereby explicitly assumes responsibility
for the matters set out below:

 

		7.1.1	to the extent feasible, satisfying itself as to the integrity of the CEO and other executive
officers and that the CEO and other executive officers create a culture of integrity throughout the organization;

 

		7.1.2	adopting of a strategic planning process and approving, on at least an annual basis, a
strategic plan which takes into account, among other things, the opportunities and risks of the Company’s business;

 

		7.1.3	the identification of the principal risks of the Company’s business and ensuring
the implementation of appropriate systems to manage these risks;

 

		7.1.4	succession planning, including appointing, training and monitoring senior management;

 

		7.1.5	adopting a communication policy for the Company; and

 

		7.1.6	the Company’s internal control and management information systems.

 

7.2                   Corporate Governance Matters – The board shall adopt and maintain corporate governance principles and guidelines
recommended to it by the Human Resources and Governance Committee and which comply with all applicable legal and stock exchange
listing requirements and with such recommendations of relevant securities regulatory authorities and stock exchanges as the board
may consider appropriate.

 

7.3                   Nomination and Appointment of Directors –

 

		7.3.1	The board shall nominate individuals for election as directors by the shareholders and
shall require the Human Resources and Governance Committee to make recommendations to it with respect to such nominations.

 

		7.3.2	The board may fill such vacancies on the board as it is permitted by law to fill and shall
require the Human Resources and Governance Committee to make recommendations to it with respect to such vacancies.

 

		7.3.3	The board shall consider recommendations made to it by the Human Resources and Governance
Committee with respect to the size and composition of the board.

 

		7.3.4	In selecting candidates for appointment or nomination as directors, the board shall:

 

		(i)	consider what competencies and skills the board, as a whole, should possess; and

 

		(ii)	assess what competencies and skills each existing director possesses.

 

    	 	C-3	 

     

    

 

7.4                    Significant Decisions – The board shall require management to obtain its approval for all significant decisions,
including major financings, acquisitions, dispositions, budgets and capital expenditures.

 

7.5                    Information Flow from Management – The board shall require management to keep it aware of the Company’s performance
and events affecting the Company’s business, including opportunities in the marketplace and adverse or positive developments.

 

7.6                    Position Descriptions – The board shall develop clear position descriptions for the chairperson of the board, the
deputy chairperson and the chair of each board committee. In addition, the board, together with the CEO, shall develop a clear
position description for the CEO.

 

7.7                    Corporate Objectives – The board shall approve specific financial and business goals and objectives, which will be
used as a basis for measuring the performance of the CEO.

 

7.8                    Delegation to Committees –

 

		7.8.1	The board shall establish and maintain the following committees of the board, each having
charters that incorporate all applicable legal and stock exchange listing requirements and with such recommendations of relevant
securities regulatory authorities and stock exchanges as the board may consider appropriate:

 

		(i)	Audit Committee; and

 

		(ii)	Human Resources and Governance Committee.

 

 

		7.8.2	Subject to the Company’s articles and by-laws, the board may appoint any other committee
of directors and delegate to such committee any of the powers of the board, except to the extent that such delegation is prohibited
under the CBCA.

 

		7.8.3	The board will appoint and maintain in office, members of each of its committees such
that the composition of each such committee is in compliance with all applicable legal and stock exchange listing requirements
and with such recommendations of relevant securities regulatory authorities and stock exchanges as the board may consider appropriate
and shall require the Human Resources and Governance Committee to make recommendations to it with respect to such matters.

 

		7.8.4	The board will review the charters and the composition of each of its committees on a
regular basis and will revise those charters or amend the composition of its committees as it considers appropriate and shall require
the Human Resources and Governance Committee to make recommendations to it with respect to such matters.

 

7.9                    Delegation to Management – Subject to the Company’s articles and by-laws, the board may designate the offices
of the Company, appoint officers, specify their duties and delegate to them powers to manage the business and affairs of the Company,
except to the extent that such delegation is prohibited under the CBCA.

 

7.10                   Residual Authority – The board retains responsibility for any matter that has not been delegated to management or
to a committee of the directors.

 

    	 	C-4	 

     

    

 

7.11                  Financial Statements – The board shall review and, if appropriate, approve the Company’s annual financial statements
after the Audit Committee has reviewed and made a recommendation on those statements to the board.

 

7.12                  Compensation Matters –

 

		7.12.1	Executive Compensation Policy – The board shall review the executive compensation
policy submitted to it by the Human Resources and Governance Committee.

 

		7.12.2	Compensation and Benefits – The board shall review and approve, as appropriate:

 

		(i)	the overall structure of the Company’s total compensation strategy, including the elements
of the Company’s annual and long-term incentive plans, including plan design, performance targets, administration and total
funds/shares reserved for payments;

 

		(ii)	the CEO’s total compensation in light of the performance assessment by the Human Resources
and Governance Committee;

 

		(iii)	the individual elements of total compensation for the executives named in the annual proxy statement
and the total compensation of such other members of senior management not named in the annual proxy statement;

 

		(iv)	the total compensation for the members of the board, in light of director compensation guidelines
and principles established by the Human Resources and Governance Committee;

 

		(v)	and shall require the Human Resources and Governance Committee to make recommendations to it with
respect to such matters.

 

		7.12.3	Organizational Responsibilities – The board shall review and approve as appropriate:

 

		(i)	appointments for all mission critical positions (as such positions are defined by the Human Resources
and Governance Committee from time to time) and compensation packages for such appointments;

 

		(ii)	executive compensation disclosure that is required to be publicly disclosed by the Company;

 

		(iii)	and shall require the Human Resources and Governance Committee to make recommendations to it with
respect to such matters.

 

		7.12.4	Pension Plan Matters – The board shall receive and review reports from management
and from the Human Resources and Governance Committee covering administration, investment performance, funding, financial impact,
actuarial reports and other pension plan related matters.

 

7.13                  Code of Ethics –

 

		7.13.1	The board shall adopt a written code of business conduct and ethics (the “Code”)
recommended to it by the Human Resources and Governance Committee and which complies with all applicable legal and stock exchange
listing requirements and with such recommendations of relevant securities regulatory authorities and stock exchanges as the board
may consider appropriate.

 

    	 	C-5	 

     

    

 

		7.13.2	The board shall be responsible for monitoring compliance with the Code. Any waivers from
the Code that are granted for the benefit of directors or executive officers of the Company shall be granted by the board (or a
committee of the board) only.

 

7.14                  Communication Policy – The Board shall periodically review the Company’s overall communications policy, including
measures for receiving feedback from stakeholders.

 

		8.	REGULAR BOARD ASSESSMENTS

 

8.1                    Establish Process – The board shall establish a process to be carried out by the Human Resources and Governance
Committee for regularly assessing the effectiveness and contribution of the board, its committees and each individual director.

 

8.2                    Amendments
to Mandate – The board will review and reassess the adequacy of its mandate on a regular basis.

 

		9.	ORIENTATION AND CONTINUING EDUCATION

 

9.1                    The board shall ensure that all new directors receive a comprehensive orientation.

 

9.2                    The board shall provide continuing education opportunities for all directors, so that individuals may maintain or enhance
their skills and abilities as directors, as well as to ensure their knowledge and understanding of the Company’s business
remains current.

 

		10.	Interpretation

 

10.1                  The provisions of this mandate shall at all times be subject to the provisions of the CBCA, the articles and the by-laws
of the Company.

 

* * *

 

This mandate is intended as a
component of the flexible governance framework within which the board, assisted by its committees, directs the affairs of
the Company. While it should be interpreted in the context of all applicable laws, regulations and listing requirements, as well
as in the context of the Company's articles and by-laws, it is not intended to establish any legally binding obligations.
The Directors have the right to derogate from the provisions of this mandate where the circumstances warrant it, to the extent
permitted by applicable laws, regulations and listing requirements and the Company's articles and by-laws.

 

    	 	C-6Exhibit 4.5

 

Condensed
Consolidated Interim Financial Statements of

(Unaudited)

 

BELLUS
HEALTH INC.

 

Periods
ended June 30, 2019 and 2018

 

    

     

    

 

Bellus
health INC.

Condensed
Consolidated Interim Financial Statements

(Unaudited)

 

Periods
ended June 30, 2019 and 2018

 

	Condensed Consolidated Interim
    Financial Statements	 
	 	 
	Condensed Consolidated
    Interim Statements of Financial Position	1
	 	 
	Condensed Consolidated
    Interim Statements of Loss and Other Comprehensive Loss	2
	 	 
	Condensed Consolidated
    Interim Statements of Changes in Shareholders’ Equity	3
	 	 
	Condensed Consolidated
    Interim Statements of Cash Flows	4
	 	 
	Notes to Condensed
    Consolidated Interim Financial Statements	5

 

    

     

    

 

bellus
health INC.

Condensed
Consolidated Interim Statements of Financial Position

(Unaudited)

 

June
30, 2019 and December 31, 2018

(in
thousands of Canadian dollars)

 

	 	 	June
    30,	 	 	December
    31,	 
	 	 	2019	 	 	2018	 
	 	 	 	 	 	 	 
	Assets	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	Current assets:	 	 	 	 	 	 	 	 
	 	Cash and
    cash equivalents (note 4)	 	$	18,030	 	 	$	14,933	 
	 	Short-term investments
    (note 4)	 	 	24,339	 	 	 	33,973	 
	 	Trade and other receivables	 	 	964	 	 	 	809	 
	 	Prepaid
    expenses	 	 	523	 	 	 	1,149	 
	 	Total
    current assets	 	 	43,856	 	 	 	50,864	 
	 	 	 	 	 	 	 	 	 	 
	Non-current assets:	 	 	 	 	 	 	 	 
	 	Right-of-use asset
    (notes 3 and 5)	 	 	227	 	 	 	—	 
	 	Other assets	 	 	85	 	 	 	77	 
	 	In-process
    research and development asset	 	 	2,359	 	 	 	2,359	 
	 	Total
    non-current assets	 	 	2,671	 	 	 	2,436	 
	Total Assets	 	$	46,527	 	 	$	53,300	 
	 	 	 	 	 	 	 	 	 	 
	Liabilities and Shareholders' Equity	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 
	Current liabilities:	 	 	 	 	 	 	 	 
	 	Trade and other payables
    (note 6)	 	$	7,046	 	 	$	2,716	 
	 	Lease
    liability (notes 3 and 5)	 	 	128	 	 	 	—	 
	 	Total
    current liabilities	 	 	7,174	 	 	 	2,716	 
	 	 	 	 	 	 	 	 	 	 
	Non-current liabilities:	 	 	 	 	 	 	 	 
	 	Lease
    liability (notes 3 and 5)	 	 	90	 	 	 	—	 
	 	Total
    non-current liabilities	 	 	90	 	 	 	—	 
	Total Liabilities	 	 	7,264	 	 	 	2,716	 
	 	 	 	 	 	 	 	 	 	 
	Shareholders' equity:	 	 	 	 	 	 	 	 
	 	Share capital (note 7 (a))	 	 	503,552	 	 	 	502,706	 
	 	Other equity (notes
    7 (b) (i) and (ii))	 	 	27,627	 	 	 	27,101	 
	 	Deficit	 	 	(491,916	)	 	 	(479,223	)
	Total Shareholders’
    Equity	 	 	39,263	 	 	 	50,584	 
	Commitments
    (note 10)	 	 	 	 	 	 	 	 
	Total Liabilities
    and Shareholders’ Equity	 	$	46,527	 	 	$	53,300	 

 

See
accompanying notes to unaudited condensed consolidated interim financial statements.

 

    1

     

    

 

bellus
health INC.

Condensed
Consolidated Interim Statements of Loss and Other Comprehensive Loss

(Unaudited)

 

Periods
ended June 30, 2019 and 2018

(in
thousands of Canadian dollars, except per share data)

 

	 	 	Three-month
    periods ended	 	 	Six-month
    periods ended	 
	 	 	June 30,	 	 	June 30,	 
	 	 	2019	 	 	2018	 	 	2019	 	 	2018	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Revenues	 	$	8	 	 	$	8	 	 	$	17	 	 	$	17	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Expenses:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	Research and development	 	 	5,616	 	 	 	997	 	 	 	8,922	 	 	 	2,402	 
	 	Research tax credits	 	 	(133	)	 	 	(116	)	 	 	(210	)	 	 	(276	)
	 	 	 	5,483	 	 	 	881	 	 	 	8,712	 	 	 	2,126	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	General and administrative	 	 	2,367	 	 	 	946	 	 	 	3,770	 	 	 	1,650	 
	 	Total operating expenses	 	 	7,850	 	 	 	1,827	 	 	 	12,482	 	 	 	3,776	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Loss
    from operating activities	 	 	(7,842	)	 	 	(1,819	)	 	 	(12,465	)	 	 	(3,759	)
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Finance income	 	 	277	 	 	 	85	 	 	 	574	 	 	 	184	 
	Finance
    costs	 	 	(337	)	 	 	(1	)	 	 	(802	)	 	 	(3	)
	Net
    finance (costs) income (note 8)	 	 	(60	)	 	 	84	 	 	 	(228	)	 	 	181	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Change
    in fair value of contingent consideration receivable	 	 	—	 	 	 	171	 	 	 	—	 	 	 	171	 
	Net
    loss and total comprehensive loss for the period	 	$	(7,902	)	 	$	(1,564	)	 	$	(12,693	)	 	$	(3,407	)
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Loss per share (note 9)	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Basic
    and diluted	 	$	(0.05	)	 	$	(0.01	)	 	$	(0.08	)	 	$	(0.03	)

 

See
accompanying notes to unaudited condensed consolidated interim financial statements.

 

    2

     

    

 

bellus
health INC.

Condensed
Consolidated Interim Statements of Changes in Shareholders’ Equity

(Unaudited)

 

Periods
ended June 30, 2019 and 2018

(in
thousands of Canadian dollars)

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Share	 	 	Other	 	 	 	 	 	 	 
	 	 	capital	 	 	equity	 	 	Deficit	 	 	Total	 
	 	 	(note 7 (a))	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Balance, December 31, 2018	 	$	502,706	 	 	$	27,101	 	 	$	(479,223	)	 	$	50,584	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Adjustment on initial application of
    IFRS 16 (note 3)	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Adjusted
    balance as at January 1, 2019	 	 	502,706	 	 	 	27,101	 	 	 	(479,223	)	 	 	50,584	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total comprehensive loss for the period:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Net loss and comprehensive
    loss	 	 	—	 	 	 	—	 	 	 	(12,693	)	 	 	(12,693	)
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total
    comprehensive loss for the period	 	 	—	 	 	 	—	 	 	 	(12,693	)	 	 	(12,693	)
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Transactions
    with shareholders, recorded directly in shareholders’ equity:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Issued
    upon stock options exercise (note 7 (b) (i))	 	 	137	 	 	 	(62	)	 	 	—	 	 	 	75	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Issued
    upon broker warrants exercise (note 7 (b) (ii))	 	 	709	 	 	 	(293	)	 	 	—	 	 	 	416	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Stock-based compensation
    (note 7 (b) (i))	 	 	—	 	 	 	881	 	 	 	—	 	 	 	881	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Balance,
    June 30, 2019	 	$	503,552	 	 	$	27,627	 	 	$	(491,916	)	 	$	39,263	 

 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Share	 	 	Other	 	 	 	 	 	 	 
	 	 	capital	 	 	equity	 	 	Deficit	 	 	Total	 
	 	 	 	(note
                                         7 (a))	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Balance, December 31, 2017	 	$	467,253	 	 	$	26,202	 	 	$	(467,167	)	 	$	26,288	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total comprehensive
    loss for the period:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Net
    loss and comprehensive loss	 	 	—	 	 	 	—	 	 	 	(3,407	)	 	 	(3,407	)
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total
    comprehensive loss for the period	 	 	—	 	 	 	—	 	 	 	(3,407	)	 	 	(3,407	)
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Transactions
    with shareholders, recorded directly in shareholders’ equity:	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Stock-based
    compensation (note 7 (b) (i))	 	 	—	 	 	 	329	 	 	 	—	 	 	 	329	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Balance,
    June 30, 2018	 	$	467,253	 	 	$	26,531	 	 	$	(470,574	)	 	$	23,210	 

  

See
accompanying notes to unaudited condensed consolidated interim financial statements.

 

    3

     

    

 

bellus
health INC.

Condensed
Consolidated Interim Statements of Cash Flows

(Unaudited)

 

Periods
ended June 30, 2019 and 2018

(in
thousands of Canadian dollars)

 

	 	 	Six-month
    periods ended	 
	 	 	June
    30,	 
	 	 	2019	 	 	2018	 
	 	 	 	 	 	 	 
	Cash flows from operating
    activities:	 	 	 	 	 	 	 	 
	 	Net
    loss for the period	 	$	(12,693	)	 	$	(3,407	)
	 	Adjustments
    for:	 	 	 	 	 	 	 	 
	 	Depreciation
    (note 5)	 	 	72	 	 	 	—	 
	 	Stock-based
    compensation	 	 	881	 	 	 	329	 
	 	Net
    finance costs (income)	 	 	228	 	 	 	(181	)
	 	Change
    in fair value of contingent consideration receivable	 	 	—	 	 	 	(171	)
	 	Other
    items	 	 	17	 	 	 	(2	)
	 	Changes
    in operating assets and liabilities	 	 	 	 	 	 	 	 
	 	Trade
    and other receivables	 	 	(155	)	 	 	189	 
	 	Prepaid
    expenses and other assets	 	 	768	 	 	 	(25	)
	 	Trade
    and other payables	 	 	4,586	 	 	 	(1,121	)
	 	Financial
    liabilities – CVRs	 	 	—	 	 	 	(20	)
	 	 	 	 	(6,296	)	 	 	(4,409	)
	 	 	 	 	 	 	 	 	 	 
	Cash flows from financing
    activities:	 	 	 	 	 	 	 	 
	 	Payment
    of lease liability	 	 	(87	)	 	 	—	 
	 	Issuance
    of common shares through equity offerings, net of share issue costs	 	 	(406	)	 	 	(290	)
	 	Issuance
    of common shares upon stock options exercise	 	 	75	 	 	 	—	 
	 	Issuance
    of common shares upon broker warrants exercise	 	 	416	 	 	 	—	 
	 	Interest
    and bank charges paid	 	 	(5	)	 	 	(3	)
	 	 	 	 	(7	)	 	 	(293	)
	 	 	 	 	 	 	 	 	 	 
	Cash flows from investing
    activities:	 	 	 	 	 	 	 	 
	 	Net
    sales of short-term investments	 	 	9,575	 	 	 	1,204	 
	 	Acquisition
    of in-process research and development asset, net of costs and deferred development support payments	 	 	—	 	 	 	475	 
	 	Proceeds
    from sale of subsidiary	 	 	—	 	 	 	400	 
	 	Interest
    received	 	 	254	 	 	 	65	 
	 	 	 	 	9,829	 	 	 	2,144	 
	Net increase (decrease)
    in cash and cash equivalents	 	 	3,526	 	 	 	(2,558	)
	 	 	 	 	 	 	 	 	 	 
	Cash and cash equivalents,
    beginning of period	 	 	14,933	 	 	 	7,749	 
	 	 	 	 	 	 	 	 	 	 
	Effect of foreign exchange
    on cash and cash equivalents	 	 	(429	)	 	 	16	 
	 	 	 	 	 	 	 	 	 	 
	Cash
    and cash equivalents, end of period	 	$	18,030	 	 	$	5,207	 
	 	 	 	 	 	 	 	 	 
	Supplemental cashflow
    disclosure:	 	 	 	 	 	 	 	 
	 	Non-cash
    transactions:	 	 	 	 	 	 	 	 
	 	Initial
    recognition of right-of-use asset and lease liability (note 3)	 	$	156	 	 	$	—	 
	 	Addition
    to right-of-use asset and lease liability – Lease modification (note 5)	 	 	143	 	 	 	—	 
	 	Share
    issue costs – 2018 equity offering, in Trade and other payables	 	 	67	 	 	 	—	 
	 	Ascribed
    value related to issuance of common shares upon stock options exercise (note 7 (b) (i))	 	 	62	 	 	 	—	 
	 	Ascribed
    value related to issuance of common shares upon broker warrants exercise (note 7 (b) (ii))	 	 	293	 	 	 	—	 

  

See
accompanying notes to unaudited condensed consolidated interim financial statements.

 

    4

     

    

 

bellus
health INC.

Notes
to Condensed Consolidated Interim Financial Statements

(Unaudited)

 

Periods
ended June 30, 2019 and 2018

(in
thousands of Canadian dollars, except per share data, unless otherwise noted)

 

 

 

1.   Reporting
entity:

 

BELLUS
Health Inc. (“BELLUS Health” or the “Company”) is a clinical-stage biopharmaceutical company developing
novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's lead product
candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus. The Company is domiciled in Canada.
The address of the Company’s registered office is 275 Armand-Frappier Blvd., Laval, Quebec, H7V 4A7.

 

These
condensed consolidated interim financial statements include the accounts of BELLUS Health Inc. and its subsidiaries.

 

The
Company's shares trade on the Toronto Stock Exchange (“TSX”) under the symbol BLU. The annual consolidated financial
statements of the Company as at and for the year ended December 31, 2018 are available at www.bellushealth.com or at www.sedar.com.

 

2.   Basis
of preparation:

 

		(a)	Statement
                                         of compliance:

 

These
condensed consolidated interim financial statements have been prepared in accordance with International Financial Reporting Standards
(“IFRS”) and International Accounting Standard (IAS) 34, Interim Financial Reporting. The condensed consolidated
interim financial statements do not include all the information required for full annual consolidated financial statements and
should be read in conjunction with the annual consolidated financial statements as at and for the year ended December 31, 2018.

 

These
condensed consolidated interim financial statements for the three and six-month periods ended June 30, 2019 were approved by the
Board of Directors on August 7, 2019.

 

		(b)	Use
                                         of estimates and judgements:

 

The
preparation of the condensed consolidated interim financial statements in accordance with IFRS requires management to make judgements,
estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities,
income and expenses. The reported amounts and note disclosures reflect management’s best estimate of the most probable set
of economic conditions and planned course of actions. Actual results may differ from these estimates.

 

In
preparing these condensed consolidated interim financial statements, the significant judgements made by management in applying
the Company’s accounting policies and key sources of estimation uncertainty were the same as those applied to the consolidated
financial statements for the year ended December 31, 2018, except for new significant judgements related to lessee accounting
under IFRS 16, which are described in note 3.

 

    5

     

    

 

bellus
health INC.

Notes
to Condensed Consolidated Interim Financial Statements (Continued)

(Unaudited)

 

Periods
ended June 30, 2019 and 2018

(in
thousands of Canadian dollars, except per share data, unless otherwise noted)

 

 

 

3.   Significant
accounting policies and basis of measurement:

 

The
accounting policies and basis of measurement applied in these condensed consolidated interim financial statements are the same
as those applied by BELLUS Health in its consolidated financial statements for the year ended December 31, 2018, except as described
below.

 

The
Company has initially adopted IFRS 16, Leases from January 1, 2019.

 

IFRS
16 introduced a single, on-balance sheet accounting model for lessees. As a result, BELLUS Health, as a lessee, has recognized
a right-of-use asset representing its rights to use the underlying asset and a lease liability representing its obligation to
make lease payments in its statement of financial position, in relation to its property lease.

 

The
Company has applied IFRS 16 using the modified retrospective approach, under which the cumulative effect of initial application
is recognized in retained earnings as at January 1, 2019. Accordingly, the comparative information presented for 2018 has not
been restated. It is presented under lAS 17, Leases and related interpretations. There was no impact to the deficit at
January 1, 2019 upon the adoption of IFRS 16.

 

The
details of the changes in accounting policies are disclosed below.

 

		(a)	Definition
                                         of a lease:

 

The
Company now assesses whether a contract is or contains a lease based on the new definition of a lease. Under IFRS 16, a contract
is, or contains, a lease if the contract conveys a right to control the use of an identified asset for a period of time in exchange
for consideration. On transition to IFRS 16, the Company elected to apply the practical expedient to grandfather the assessment
of which transactions are leases. It applied IFRS 16 only to contracts that were previously identified as leases. Contracts that
were not identified as leases under lAS 17 and IFRIC 4 were not reassessed. Therefore, the definition of a lease under IFRS 16
has been applied only to contracts entered into or changed on or after January 1, 2019.

 

At
inception or on reassessment of a contract that contains a lease component, BELLUS Health allocates the consideration in the contract
to each lease and non-lease component on the basis of their relative stand-alone prices. However, for its lease of property in
which it is a lessee, the Company has elected not to separate non-lease components and will instead account for the lease and
non-lease components as a single lease component.

 

    6

     

    

 

bellus
health INC.

Notes
to Condensed Consolidated Interim Financial Statements (Continued)

(Unaudited)

 

Periods
ended June 30, 2019 and 2018

(in
thousands of Canadian dollars, except per share data, unless otherwise noted)

 

 

 

3.   Significant
accounting policies and basis of measurement (continued):

 

		(b)	As
                                         a lessee:

 

		(i)	Significant
                                         accounting policies:

 

BELLUS
Health recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially
measured at cost, and subsequently at cost less any accumulated depreciation and impairment losses, and adjusted for certain remeasurements
of the lease liability. The right-of-use asset is depreciated using the straight-line method from the commencement date to the
earlier of the end of the useful life of the asset or the end of the lease term.

 

The
lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted
using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing
rate. Generally, the Company uses its incremental borrowing rate as the discount rate.

 

The
lease liability is subsequently increased by the interest cost on the lease liability and decreased by lease payment made. It
is remeasured when there is a change in future lease payments arising from a change in an index or rate, a change in the estimate
of the amount expected to be payable under a residual value guarantee, or as appropriate, changes in the assessment of whether
a purchase or extension option is reasonably certain to be exercised or a termination option is reasonably certain not to be exercised.

 

		(ii)	Transition:

 

Prior
to January 1, 2019, BELLUS Health classified its property lease as an operating lease under lAS 17.

 

		(c)	Impacts
                                         on consolidated financial statements:

 

		(i)	Impacts
                                         on transition:

 

On
transition to IFRS 16, BELLUS Health recognized a right-of-use asset and a lease liability, recognising the difference in retained
earnings. The impact on transition is summarised below:

 

	 	 	January
    1,	 
	 	 	2019	 
	 	 	 	 
	Right-of-use
    asset	 	$	156	 
	Lease
    liability	 	 	(156	)

 

    7

     

    

 

bellus
health INC.

Notes
to Condensed Consolidated Interim Financial Statements (Continued)

(Unaudited)

 

Periods
ended June 30, 2019 and 2018

(in
thousands of Canadian dollars, except per share data, unless otherwise noted)

 

 

 

3.   Significant
accounting policies and basis of measurement (continued):

 

		(c)	Impacts
                                         on consolidated financial statements (continued):

 

		(i)	Impacts
                                         on transition (continued):

 

When
measuring the lease liability for the property lease that was classified as an operating lease, the Company discounted the remaining
lease payments using its incremental borrowing rate as at January 1, 2019. The rate applied is 5%.

 

	 	 	January
    1,	 
	 	 	2019	 
	 	 	 	 
	Operating
    lease commitment as at December 31, 2018 as disclosed in the Company’s consolidated financial statements	 	$	164	 
	Discounting
    of lease payments	 	 	(8	)
	Lease
    liability recognized as at January 1, 2019	 	$	156	 

 

		(ii)	Impacts
                                         for the period:

 

Under
IFRS 16, the Company has recognized depreciation and interest expense on its right-of-use asset and lease liability, respectively,
instead of an operating lease expense. During the three and six-month periods ended June 30, 2019, the Company recognized in its
condensed consolidated interim statement of loss and other comprehensive loss $36 and $72 of depreciation expense, respectively
(of which $25 and $50 respectively is presented in Research and development expenses and $11 and $22 respectively is presented
in General and administrative expenses) and $3 and $6 of interest expense respectively, presented in Finance costs, from its property
lease. For the three and six-month periods ended June 30, 2018, the Company recognized $37 and $73 of operating lease expense,
respectively.

 

    8

     

    

 

bellus
health INC.

Notes
to Condensed Consolidated Interim Financial Statements (Continued)

(Unaudited)

 

Periods
ended June 30, 2019 and 2018

(in
thousands of Canadian dollars, except per share data, unless otherwise noted)

 

 

 

4.   Cash,
cash equivalents and short-term investments:

 

Cash,
cash equivalents and short-term investments consist of cash balances with banks and short-term investments:

 

	 	 	June
    30,	 	 	December
    31,	 
	 	 	2019	 	 	2018	 
	 	 	 	 	 	 	 
	Cash
    balances with banks	 	$	6,313	 	 	$	1,464	 
	Short-term
    investments with initial maturities of less than three months (yielding interest at 1.70% to 1.95% as at June 30, 2019) (December
    31, 2018 – 1.70% to 1.95%)	 	 	11,717	 	 	 	13,469	 
	Cash
    and cash equivalents	 	 	18,030	 	 	 	14,933	 
	 	 	 	 	 	 	 	 	 
	Short-term
    investments with initial maturities greater than three months and less than one year (yielding interest at 1.95% to
    3.10% as at June 30, 2019) (December 31, 2018 – 1.90% to 3.10%)	 	 	24,339	 	 	 	33,973	 
	Cash,
    cash equivalents and short-term investments	 	$	42,369	 	 	$	48,906	 

 

5.   Right-of-use
asset and lease liability: 

 

BELLUS
Health Inc. leases office space in Laval, Quebec. An amendment to the Company’s property lease was signed on June 25,
2019, extending the property lease by an additional one-year term beyond the initial expiry on January 30, 2020, to January 30,
2021.

 

Right
of use asset:

 

	 	 	Net
    book	 
	 	 	value	 
	 	 	 	 
	Cost:	 	 	 	 
	Balance as at January 1, 2019	 	$	156	 
	Addition
    to right-of-use asset – Lease modification	 	 	143	 
	Balance
    as at June 30, 2019	 	$	299	 
	 	 	 	 	 
	Accumulated amortization:	 	 	 	 
	Balance as at January 1, 2019	 	$	—	 
	Depreciation
    expense for the period	 	 	(72	)
	Balance
    as at June 30, 2019	 	$	(72	)
	 	 	 	 	 
	Net book value:	 	 	 	 
	Balance as at January 1, 2019	 	$	156	 
	Balance
    as at June 30, 2019	 	$	227	 

 

    9

     

    

 

bellus
health INC.

Notes
to Condensed Consolidated Interim Financial Statements (Continued)

(Unaudited)

 

Periods
ended June 30, 2019 and 2018

(in
thousands of Canadian dollars, except per share data, unless otherwise noted)

 

 

 

5.    Right-of-use
asset and lease liability (continued): 

 

Lease
liability:

 

	 	 	Carrying	 
	 	 	value	 
	 	 	 	 
	Balance as at January 1, 2019	 	$	156	 
	 	 	 	 	 
	Addition to lease liability – Lease
    modification	 	 	143	 
	 	 	 	 	 
	Interest expense	 	 	6	 
	Lease
    payments	 	 	(87	)
	Balance as at June 30, 2019	 	$	218	 
	Current
    portion of lease liability	 	 	128	 
	Non-current
    portion of lease liability	 	$	90	 

 

The
remaining life of the Company’s property lease as of June 30, 2019 is 1.6 years,

 

Lease
payments were discounted using an incremental borrowing rate of 5%.

 

Minimum
annual payments under the non-cancelable property lease, undiscounted, are as follows:

 

	Years
    ending December 31,	 	 	 
	 	 	 	 
	2019	 	$	64	 
	2020	 	 	156	 
	2021	 	 	13	 
	 	 	$	233	 

 

6.   Trade
and other payables:

 

Trade
and other payables consist of:

 

	 	 	June
    30,	 	 	December
    31,
	 	 	2019	 	 	2018
	 	 	 	 
	Trade
    payables	 	$	405	 	 	$555
	Other accrued liabilities	 	 	4,276	 	 	1,495
	Deferred
    share unit plans (note 7 (b) (iii))	 	 	2,365	 	 	666
	 	 	$	7,046	 	 	$2,716

 

    10

     

    

  

bellus
health INC.

Notes
to Condensed Consolidated Interim Financial Statements (Continued)

(Unaudited)

 

Periods
ended June 30, 2019 and 2018

(in
thousands of Canadian dollars, except per share data, unless otherwise noted)

 

 

 

7.   Shareholders’
equity:

 

		(a)	Share
                                         capital:

 

Issued
and outstanding common shares are as follows:

 

	 	 	Number	 	 	Dollars	 
	 	 	 	 	 	 	 
	Balance, December 31, 2018	 	 	157,039,686	 	 	$	502,706	 
	Issued upon stock options exercise (note
    7 (b) (i))	 	 	150,000	 	 	 	137	 
	Issued
    upon broker warrants exercise (note 7 (b) (ii))	 	 	1,094,923	 	 	 	709	 
	Balance,
    June 30, 2019	 	 	158,284,609	 	 	$	503,552	 

 

 

		(b)	Share-based
                                         payment arrangements:

 

		(i)	Stock
                                         option plan:

 

Changes
in outstanding stock options issued under the stock option plan for the six-month periods ended June 30, 2019 and 2018 were as
follows:

 

	 	 	 	Number	 	 	Weighted
    
average 
exercise price	 
	 	 	 	 	 	 	 	 
	Balance,
    December 31, 2018	 	 	 	11,593,000	 	 	$	0.44	 
	Granted (1)	 	 	 	3,655,000	 	 	 	1.21	 
	Exercised	 	 	 	(150,000	)	 	 	0.50	 
	Balance,
    June 30, 2019	 	 	 	15,098,000	 	 	$	0.60	 

 

	 	 	 	Number	 	 	Weighted
    
average 
exercise price	 
	 	 	 	 	 	 	 	 
	Balance,
    December 31, 2017	 	 	 	7,293,000	 	 	$	0.44	 
	Granted
    (2)	 	 	 	4,150,000	 	 	 	0.35	 
	Balance,
    June 30, 2018	 	 	 	11,443,000	 	 	$	0.41	 

 

		(1)	3,225,000
                                         stock options were granted to key management personnel and 430,000 were granted to other
                                         employees.

		(2)	3,800,000
                                         stock options were granted to key management personnel and 350,000 were granted to other
                                         employees.

 

    11

     

    

 

bellus
health INC.

Notes
to Condensed Consolidated Interim Financial Statements (Continued)

(Unaudited)

 

Periods
ended June 30, 2019 and 2018

(in
thousands of Canadian dollars, except per share data, unless otherwise noted)

 

 

 

7.   Shareholders’
equity (continued):

 

		(b)	Share-based
                                         payment arrangements (continued):

 

		(i)	Stock
                                         option plan (continued):

 

The
following table summarizes information about stock options outstanding and exercisable as at June 30, 2019:

 

	 	 	 	Options
    outstanding	 	 	Options
    exercisable	 
	 	 	 	 	 	 	Weighted	 	 	 	 
	 	 	 	 	 	 	average	 	 	 	 
	 	 	 	 	 	 	years to	 	 	 	 
	Exercise price/share	 	 	Number	 	 	expiration	 	 	Number	 
	$0.30	 	 	 	2,630,000	 	 	 	7.8	 	 	 	1,079,000	 
	$0.35	 	 	 	4,150,000	 	 	 	8.6	 	 	 	830,000	 
	$0.42	 	 	 	200,000	 	 	 	8.4	 	 	 	40,000	 
	$0.50	 	 	 	4,150,000	 	 	 	3.2	 	 	 	4,150,000	 
	$0.57	 	 	 	150,000	 	 	 	9.0	 	 	 	—	 
	$1.05	 	 	 	60,000	 	 	 	3.2	 	 	 	60,000	 
	$1.12	 	 	 	103,000	 	 	 	6.7	 	 	 	61,800	 
	$1.21	 	 	 	3,655,000	 	 	 	9.7	 	 	 	—	 
	 	 	 	 	15,098,000	 	 	 	7.2	 	 	 	6,220,800	 

 

Stock-based
compensation

 

For
the three and six-month periods ended June 30, 2019, the Company recorded a stock-based compensation expense related to the
stock option plan (excluding compensation under the DSU plan) in the amount of $537 and $881, respectively, in the condensed consolidated
interim statement of loss and other comprehensive loss; from these amounts, $93 and $153, respectively, is presented in Research
and development expenses and $444 and $728, respectively, is presented in General and administrative expenses ($199 and $329 for
the corresponding periods of the previous year, $29 and $49 respectively presented in Research and development expenses and $170
and $280 respectively presented in General and administrative expenses).

 

    12

     

    

 

bellus
health INC.

Notes
to Condensed Consolidated Interim Financial Statements (Continued)

(Unaudited)

 

Periods
ended June 30, 2019 and 2018

(in
thousands of Canadian dollars, except per share data, unless otherwise noted)

 

 

 

7.   Shareholders’
equity (continued):

 

		(b)	Share-based
                                         payment arrangements (continued):

 

		(i)	Stock
                                         option plan (continued):

 

Stock-based
compensation (continued)

 

The
fair value of each stock option granted is estimated on the date of grant using the Black-Scholes pricing model. Expected volatility
is estimated by considering historic average share price volatility for a period commensurate with the expected life. The weighted
average assumptions for stock options granted during the six-month periods ended June 30, 2019 and 2018 were as follows:

 

	 	 	2019
    (1)	 	 	2018
    (2)	 
	 	 	 	 	 	 	 
	Weighted
    average fair value of stock options at grant date	 	$	1.04	 	 	$	0.28	 
	Weighted average share price	 	$	1.21	 	 	$	0.35	 
	Weighted average exercise price	 	$	1.21	 	 	$	0.35	 
	Risk-free interest rate	 	 	1.83	%	 	 	2.19	%
	Expected volatility	 	 	100	%	 	 	100	%
	Expected life in years	 	 	7	 	 	 	7	 
	Expected
    dividend yield	 	 	Nil	 	 	 	Nil	 

 

		(1)	All
                                         stock options were granted on February 20, 2019.

		(2)	All
                                         stock options were granted on February 20, 2018.

 

Dividend
yield was excluded from the calculation, since it is the present policy of the Company to retain all earnings to finance operations
and future growth.

 

		(ii)	Broker
                                         warrants:

 

Changes
in outstanding broker warrants for the six-month period ended June 30, 2019 were as follows:

 

	 	 	 	Number	 	 	Dollars	 
	 	 	 	 	 	 	 	 
	Balance, December 31, 2018	 	 	 	2,556,999	 	 	$	683	 
	Exercised	 	 	 	(1,094,923	)	 	 	(293	)
	Expired	 	 	 	(11,812	)	 	 	(3	)
	 	 	 	 	 	 	 	 	 	 
	Balance,
    June 30, 2019	 	 	 	1,450,264	 	 	$	387	 

 

 

    13

     

    

 

bellus
health INC.

Notes
to Condensed Consolidated Interim Financial Statements (Continued)

(Unaudited)

 

Periods
ended June 30, 2019 and 2018

(in
thousands of Canadian dollars, except per share data, unless otherwise noted)

 

 

 

7.   Shareholders’
equity (continued):

 

		(b)	Share-based
                                         payment arrangements (continued):

 

		(ii)	Broker
                                         warrants (continued):

 

During
the six-month period ended June 30, 2019, the Company issued a total of 1,094,923 common shares from treasury upon the exercise
of a total of 1,094,923 broker warrants issued in connection with the Company’s equity offering in December 2017. As a result
of their exercise, the aggregate carrying value of the broker warrants of $293, initially allocated to Other equity pending the
issuance of common shares, was reclassified to Share capital. During the six-month period ended June 30, 2019, 11,812 broker warrants
expired, having a carrying value of $3.

 

In
July 2019, the Company issued a total of 832,540 common shares from treasury upon the exercise of a total of 832,540 broker warrants
issued in connection with the Company’s equity offering in December 2018, for total proceeds of $791. These broker warrants
have an aggregate carrying value of $222, initially allocated to Other equity pending the issuance of common shares.

 

		(iii)	Deferred
                                         share unit (“DSU”) plan:

 

Changes
in the number of units outstanding for the six-month periods ended June 30, 2019 and 2018 were as follows:

 

	Number
    of units	 	2019	 	 	2018	 
	Balance, beginning of period	 	 	652,868	 	 	 	217,953	 
	Units
    granted (1)	 	 	191,812	 	 	 	435,108	 
	Balance,
    end of period	 	 	844,680	 	 	 	653,061	 
	Balance
    of DSU liability, in Trade and other payables (2)	 	$	2,365	 	 	$	340	 

 

		(1)	All
                                         DSUs were granted to key management personnel.

		(2)	Balance
                                         of DSU liability as at December 31, 2018 amounted to $666.

 

During
the six-month period ended June 30, 2019, the Company granted 191,812 DSUs having a fair value per unit of $1.42 (435,108 DSUs
having a fair value per unit of $0.55 during the six-month period ended June 30, 2018). The stock-based compensation expense related
to the DSU plan recorded in the condensed consolidated interim statement of loss for the three and six-month periods ended June
30, 2019 amounted to $1,088 and $1,549, respectively; from these amount, $3 and $3, respectively, is presented in Research
and development expenses and $1,085 and $1,546, respectively, is presented in General and administrative expenses ($193 and $259
for the corresponding periods of the previous year, presented in General and administrative expenses).

 

    14

     

    

 

bellus
health INC.

Notes
to Condensed Consolidated Interim Financial Statements (Continued)

(Unaudited)

 

Periods
ended June 30, 2019 and 2018

(in
thousands of Canadian dollars, except per share data, unless otherwise noted)

 

 

 

8.   Net
finance (costs) income:

 

Finance
income and Finance costs for three-month periods ended June 30, 2019 and 2018 were attributed as follows:

 

	 	 	Three-month
    periods ended	 	 	Six-month
    periods ended	 
	 	 	June 30,	 	 	June 30,	 
	 	 	2019	 	 	2018	 	 	2019	 	 	2018	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Interest income	 	$	277	 	 	$	83	 	 	$	574	 	 	$	170	 
	Foreign
    exchange gain	 	 	—	 	 	 	2	 	 	 	—	 	 	 	14	 
	Finance
    income	 	 	277	 	 	 	85	 	 	 	574	 	 	 	184	 
	Interest expense on lease liability (note
    3)	 	 	(3	)	 	 	—	 	 	 	(6	)	 	 	—	 
	Interest and bank charges	 	 	(2	)	 	 	(1	)	 	 	(5	)	 	 	(3	)
	Foreign
    exchange loss	 	 	(332	)	 	 	—	 	 	 	(791	)	 	 	—	 
	Finance
    costs	 	 	(337	)	 	 	(1	)	 	 	(802	)	 	 	(3	)
	Net
    finance (costs) income	 	$	(60	)	 	$	84	 	 	$	(228	)	 	$	181	 

 

9.   Loss
per share: 

 

	 	 	Three-month
    periods ended	 	 	Six-month
    periods ended	 
	 	 	June 30,	 	 	June 30,	 
	 	 	2019	 	 	2018	 	 	2019	 	 	2018	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Basic
    weighted average number of common shares outstanding	 	 	158,110,962	 	 	 	119,497,581	 	 	 	157,769,328	 	 	 	119,497,581	 
	Basic
    and diluted loss per share	 	$	(0.05	)	 	$	(0.01	)	 	$	(0.08	)	 	$	(0.03	)

 

Excluded
from the calculation of the diluted loss per share for the three and six-month periods ended June 30, 2019 and 2018 is the impact
of all stock options granted under the stock option plan and broker warrants, as they would be anti-dilutive.

 

Stock
options granted under the stock option plan and broker warrants could potentially be dilutive in the future.

 

10.  Commitments:

 

Contracts
in the normal course of business:

 

The
Company enters into contracts in the normal course of business, including for research and development activities, consulting
and other services.

 

As
at June 30, 2019, the Company has commitments for expenditures related to contracts for research and development activities of
approximately $12,156 (approximately $6,785 as at December 31, 2018), of which $9,571 is expected to be paid in 2019, $2,466 in
2020 and $119 in 2021.

 

    15

     

    

 

bellus
health INC.

Notes
to Condensed Consolidated Interim Financial Statements (Continued)

(Unaudited)

 

Periods
ended June 30, 2019 and 2018

(in
thousands of Canadian dollars, except per share data, unless otherwise noted)

 

 

 

11.  Related
party transactions:

 

		(a)	There
                                         is no single ultimate controlling party.

 

		(b)	Dr.
                                         Francesco Bellini, Chairman of the Board of Directors, provides ongoing advisory services
                                         to the Company under the terms of a consulting and services agreement between the Company
                                         and Picchio International, wholly-owned by Dr. Francesco Bellini and his spouse. The
                                         agreement has a one-year term and shall renew for successive one-year terms. The Company
                                         recorded fees and expenses of $95 and $190 respectively for both three and six-month
                                         periods ended June 30, 2019 and 2018.

 

		(c)	Key
                                         management personnel:

 

The
Chief Executive Officer, Vice-Presidents and Directors of BELLUS Health are considered key management personnel of the Company.

 

The
aggregate compensation for the three and six-month periods ended June 30, 2019 and 2018 to key management personnel of the Company
is set out below:

 

	 	 	Three-month
    periods ended	 	 	Six-month
    periods ended	 
	 	 	June 30,	 	 	June 30,	 
	 	 	2019	 	 	2018	 	 	2019	 	 	2018	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Short term benefits	 	$	478	 	 	$	416	 	 	$	961	 	 	$	864	 
	DSU plan expense	 	 	1,088	 	 	 	193	 	 	 	1,549	 	 	 	259	 
	Stock option plan expense	 	 	473	 	 	 	180	 	 	 	776	 	 	 	297	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	$	2,039	 	 	$	789	 	 	$	3,286	 	 	$	1,420	 

 

12. Financial
instruments:

 

Carrying
values and fair values:

 

Fair
value estimates are made as of a specific point in time, using available information about the financial instrument. These estimates
are subjective in nature and may not be determined with precision. A three-tier fair value hierarchy prioritizes the inputs used
in measuring fair value.

 

There
was no financial asset or liability fair valued on a recurring basis as at June 30, 2019 and December 31, 2018.

 

For
its financial assets and liabilities measured at amortized cost as at June 30, 2019, the Company has determined that the
carrying value of its short-term financial assets and liabilities approximates their fair value because of the relatively short
periods to maturity of these instruments.

 

    16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]